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Brain metastasis affects 10-30% of cancer patients. Treatments such as surgery, 
chemotherapy, and radiation are mainly palliative and ineffective. In order to 
study resistance to radiotherapy, we have developed a model of brain metastasis 
receiving whole brain radiation therapy (WBRT). We aim to identify mediators of 
radiation resistance to develop new strategies to sensitize brain metastasis. 
Several clinically relevant WBRT protocols were applied to lung and breast 
adenocarcinoma models of brain metastasis that were highly sensitive to 
radiation in vitro. However, none of them impaired the growth rate of metastases 
or increased mice survival in vivo, mimicking the outcomes of recent clinical trials 
using WBRT in patients with brain metastases. Based on the different sensitivity 
comparing in vitro versus in vivo we hypothesized that resistance to radiation 
could be modulated. Indeed, brain metastatic (BrM) cells grown in organotypic 
cultures dramatically decreased their sensitivity to radiation. Transcriptomic 
analysis of a BrM cell line under culture conditions correlating with low or high 
sensitivity to radiation was performed. The top candidate S100A9, as well as a 
known receptor and downstream signalling pathway, were all upregulated in 
conditions involving resistance to radiation. 
Although targeting S100A9 in BrM models did not impair the ability to generate 
brain metastasis, when combined with WBRT a significant reduction in tumour 
burden was evident. Similarly, an inhibitor blocking S100A9 mediated activation 
of NFκβ reproduced this finding suggesting a potential therapeutic implication. 
Analysis of S100A9 levels in human samples reflected inter-patient 
heterogeneity, suggesting its potential as a biomarker to personalize the use of 








La metástasis cerebral afecta a entre el 10 y el 30% de los pacientes con cáncer. 
Los tratamientos como la cirugía, la quimioterapia y la radiación son 
principalmente paliativos e ineficaces. Para estudiar la resistencia a la 
radioterapia, hemos desarrollado un modelo para el estudio de metástasis 
cerebrales tratadas con radioterapia total del cerebro (WBRT). Nuestro objetivo 
es identificar mediadores de la resistencia a la radiación y desarrollar nuevas 
estrategias para sensibilizar la metástasis cerebral. Hemos aplicado, a los 
modelos de metástasis cerebrales de adenocarcinoma de pulmón y mama que 
eran altamente sensibles a la radiación in vitro, varios protocolos WBRT 
clínicamente relevantes. Sin embargo, ninguno de ellos redujo la tasa de 
crecimiento de metástasis, o aumentó la supervivencia de los ratones in vivo. 
Nuestros resultados fueron similares a los obtenidos en ensayos clínicos 
recientes que utilizan WBRT en pacientes con metástasis cerebrales. En base a 
la diferente sensibilidad comparando experimentos in vitro versus in vivo, 
planteamos la hipótesis de que la resistencia a la radiación podría ser modulada. 
De hecho, las células metastásicas cerebrales (BrM) que crecen en cultivos 
organotípicos disminuyeron drásticamente su sensibilidad a la radiación. Se 
realizó un análisis transcriptómico de una línea celular BrM en condiciones de 
cultivo que se correlacionan con baja o alta sensibilidad a la radiación. El 
potencial mediador de la resistencia a la radiación, S100A9, así como uno de sus 
receptores conocidos, RAGE, y una de sus rutas de señalización, 
S100A9/RAGE/NFκβ, estaban todos upregulados en condiciones que implican 
resistencia a la radiación. 
Aunque al disminuir la expresión de S100A9 en los modelos BrM no perjudicaba 
la capacidad de generar metástasis cerebrales, cuando se combinaba con 
WBRT era evidente una reducción significativa en la carga tumoral. De manera 
similar, un inhibidor que bloquea la activación de NFκβ mediada por S100A9 
reprodujo este hallazgo sugiriendo una posible implicación terapéutica. El 
análisis de los niveles de S100A9 en muestras humanas reflejó la 
heterogeneidad entre pacientes, lo que sugiere su potencial como biomarcador 









Cancer is considered to be the epidemic disease of the XXI century, as the 
number of people affected is on the rise and advanced-stage disease has 
become more common in recent years (Kaidar-Person, Bar-Sela and Person, 
2011). Early in the disease process, various factors, including genetic as well as 
environmental factors, contribute to the accumulation of genetic damage and 
errors over time, particularly in dividing cells (Hanahan and Weinberg, 2000). 
Accumulation of somatic mutations is believed to influence a vast majority of 
cellular programs at various levels including the transcriptome, epigenome, and 
proteome, that favour an altered cellular state which is characterized by the 
aggressive phenotype defining cancerous cells (Hanahan and Weinberg, 2000). 
Some classical characteristics of this aggressive phenotype have been 
extensively reviewed and proposed to consist of uncontrolled growth and spread 
of these “immortal cells” that alter the normal function of the organs affected. 
Sometimes, these cells also have the ability to escape the primary organ and 
colonize a secondary site, resulting in a metastatic tumour. 
 Metastatic disease  
Metastatic disease is the last stage of progression of a malignant tumour and the 
result of a complex and multi-step process (Massague, Batlle and Gomis, 2017). 
Importantly, metastases are a significant source of morbidity and mortality for 
most cancer patients (Ferlay et al., 2015).It is estimated that approximately 90% 
of deaths related to cancer are linked to metastatic disease, due to metastatic 
spread, cachexia and organ dysfunction and other comorbidities (Seyfried and 
Huysentruyt, 2013).  
Metastatic disease imposes several challenges in terms of treatment. Certainly, 
a main challenge is to determine what kind of treatment will be the best one for 
metastases. Clinical observations and previous results available in the literature, 
suggest that the response of metastases to different treatment regimens may 
differ from the response to the very same treatment observed in the context of a 




Pattabiraman and Weinberg, 2017). During the metastatic cascade, cancer cells 
are exposed to and experience a variety of different stressors that depend on the 
context and localization (e.g. when in transit in blood circulation or after 
successful dissemination when they colonize a new tissue environment present 
in another tissue/organ). As a consequence of these stressors and the selection 
process, cancer cell clones with mutations that favour their viability under such 
conditions will preferentially survive. Thus, the metastatic tumour can differ 
genetically from the primary tumour (Brastianos et al., 2015). It is also evident 
based on clinical observations that different primary tumours present specific 
tropisms to different metastatic sites (Bos et al., 2009; Nguyen, Bos and 
Massague, 2009). It is also observed in the clinic that different types of cancer, 
despite having the same metastatic tropism, develop differences in the kinetics 
of colonizing secondary organs (Klein, 2009).  For instance, breast cancer 
patients typically experience disease recurrence years or decades after initial 
treatment (Harbeck et al., 2019). Conversely, lung cancer metastasis usually 
appears a few weeks or months after diagnosis (Cho et al., 2019).  
In summary, cancer cell specific properties (genetic, tropism and kinetics) will 
influence many aspects of metastatic progression. Therefore, a deeper 
understanding of the underlying biology of metastasis is of outmost importance 
in order to develop novel and more effective therapies. 
 Brain metastasis 
Brain metastasis is an important cause of loss of quality of life and death in 
patients afflicted with different cancer types. Although our understanding of the 
biology underlying brain metastasis is improving, we are still far from 
understanding the underlying mechanisms in their entirety, and there is an urgent 
need to develop improved therapies to treat and prevent brain metastases.  
It has been shown in multiple tumour types that brain metastases are molecularly 
distinct from both the primary tumour and extracranial metastases (Brastianos et 
al., 2015). Moreover, it is now understood that the microenvironment plays a 
significant role in metastases; the “seed and soil” hypothesis suggests that the 




the outcome of the metastasis (Psaila and Lyden, 2009; Liu et al., 2017; Peinado 
et al., 2017). 
2.1. Epidemiology of brain metastasis 
Brain metastases (BrM) are the most commonly diagnosed central nervous 
system tumour in the United States (Kaal et al., 2005; Nayak et al., 2012). The 
global incidence of brain metastasis is unknown, however the estimated range is 
7-14 per 100,000 (Fox et al., 2011). These tumours are believed to occur as much 
as 10 times more frequently than primary malignant brain tumours. (Gavrilovic 
and Posner, 2005; Kaal et al., 2005; Nathoo et al., 2005; Fox et al., 2011; Davis 
et al., 2012; Nayak et al., 2012; Feng et al., 2015; Villano et al., 2015).  
Among cancer patients, estimates for the frequency of these tumours vary 
significantly, however, previous studies have reported that they occur in 8,5–10% 
of all cancer diagnoses (Schouten et al., 2002; Barnholtz-Sloan et al., 2004). 
These estimates are likely low, due to the date in which these studies were 
published. Imaging and histology technologies were incomplete, and cerebral 
disease was not considered in patients with symptomatic advanced cancer, 
which could cause the difference between the incidence of brain metastasis in 
the past and nowadays. 
Over the last decade, metastatic brain cancer represents an increasing 
neurological problem among cancer patients. This trend may be explained by the 
increased incidence of cancer associated with a decline of mortality in cancer 
patients. This fact is explained by an improvement of diagnostic techniques (e.g. 
MRI, TC, PET), and more effective treatment of the primary tumour and 
extracranial metastasis. Consequently, there has been an increase in patient 
survival, which generates a longer period of time for cancer to get the chance to 
colonize the brain. Since brain metastasis is associated with later stages of the 
disease in cancer patients, it is expected to observe an increase on brain 
metastasis incidence as more patients survive into later phases of the disease 
(Yamanaka, 2009; Steeg, Camphausen and Smith, 2011).   
Between 10% to 30% of patients with cancer with eventually present with brain 




(Barnholtz-Sloan et al., 2004; Nayak, Lee and Wen, 2012; Tabouret et al., 2012). 
Brain metastasis diagnose is per se a poor survival prognostic factor, 
independent of primary tumour type (Hall et al., 2000). Most of the patients will 
develop severe neurological deficits and will eventually die as the disease 
progresses. It is known that brain metastasis is the cause of death of 52% of 
patients with neurological disease (Neal et al., 2014; McTyre et al., 2017). 
In terms of survival, prognostic factors for patients with brain metastases include 
age (patients ≥ 65years present a poorer disease outcome), functional status at 
diagnosis (Karnofsky Performance Score (KPS) <70 is a poor prognostic factor), 
number of metastatic lesions (more lesions correlates with worse prognosis), and 
primary disease outcome (uncontrol primary disease is a signal of worse 
prognosis), among others.(Nieder et al., 2011; Soffietti et al., 2017). Outcome 
also varies among cancer types; patients with brain metastases secondary to 
prostate cancer, bronchioloalveolar carcinoma, and breast cancer displayed the 
longest median survival with 12, 10, and 10 months, respectively (Nieder et al., 
2011).  
2.2. Main sources of brain metastasis 
Theoretically, any type of cancer can spread to the brain and generate a brain 
metastasis. However, as explained above, cancer cells vary in their tropism to 
metastasize to various sites (Obenauf and Massagué, 2015).  
The brain as a metastatic site is not an exception to this rule, and we know that 
some types of cancer intrinsically display a higher tropism to the brain than other 
types of cancer (Obenauf and Massagué, 2015; Chen et al., 2018; Yuzhalin and 
Yu, 2019). Clinical evidence shows that brain metastases are more frequent in 
patients with lung (20-56% of the patients), breast (5-20% of the patients) and 
melanoma primary tumours (7-16% of the patients) (Barnholtz-Sloan et al., 2004; 
Sperduto et al., 2010; Nayak, Lee and Wen, 2012; Berghoff et al., 2016).  
The risk of developing brain metastasis depends on various characteristics of the 
primary tumour, such as molecular subtype of the tumours and the stage of the 
development of the disease. Some literature report that patients that present 




HER2+ breast cancer and triple negative breast cancer present higher incidence 
and risk of developing brain metastasis (Martin et al., 2017). Additionally, 
advanced primary tumours present higher risk to develop brain metastasis.  At 
the following table we can find some of the main sources of brain metastasis and 
its characteristics in terms of incidence, time of diagnostic and clinical 
presentation. 
 Table 1: Most common types of cancer that form brain metastasis  
 
2.3. Mechanisms of brain colonization by metastatic cells 
The pathophysiology of metastasis involves a multi-step process where cancer 
cells must survive severe environmental challenges in order to colonize distant 
sites (Obenauf and Massagué, 2015). When considering metastatic colonization 
of the brain, the process is even more selective due to the blood brain barrier and 
Lung cancer 
• Represents the most common type of brain metastases in both men and women 
• The brain tumour is often found before, or at the same time, or soon after the 
primary tumour (average 6 to 9 months) 
• Multiple brains metastases are common 
Breast cancer 
• Represents the second most common type of brain metastases in women 
• Metastases tend to occur a few years after the diagnosis (average 2 -2.5 years), but 
metastases at 5- or 10-years post treatment are not unusual 
• They are generally found in younger and premenopausal women 
• They are more common in women with triple negative or HER2/Neu+ breast cancer 
• Two or more metastatic brain tumours are common 
Melanoma 
• Represents the second most common type of brain metastases in men 
• These cancers may metastasize to the brain and/or the meninges 
• Metastases tend to occur several years after the primary melanoma 
• Multiple brain metastases are common 
• Metastatic melanoma tumours are rich with blood vessels that have a high 




the various different elements of the microenvironment of the brain (Er et al., 
2018; Valiente et al., 2018).  
2.3.1. Extravasation of cancer cells. 
In order to colonize new organs, cancer cells must first travel through the blood 
flow from primary tumour to distant organ sites. Cancer cells need to extravasate 
from capillaries into the tissue interstice.  
The most common areas of extravasation in the brain are zones of narrowing 
cerebral microvasculature. Because of the vasculature distribution in the brain, 
previous studies have shown that 80% of brain metastases occur in the 
hemispheres, 15% in the cerebellum, and 5% in the brainstem (Patchell, 1995; 
Saha et al., 2013). After extravasating, cancer cells will remain in close contact 
with the blood vessels.   
In the specific case of the brain, cancer cells will be physically trapped in small 
capillaries with low perfusion where they require between 3 to 7 days to be able 
to successfully cross the blood brain barrier (BBB). Previous work showed that 
the process of extravasation in the brain, requires more time than in other organs 
colonized by the same cancer cells. To cross the BBB, it is necessary to combine 
several molecular mediators of extravasation (i.e. HBEGF, COX2) with 
proteases, cells surface modifications, extracellular vesicles and secreted growth 
factors. All these conditions will be a requirement to a succeed in extravasation 
into the brain tissue (Valiente et al., 2018; Arvanitis, Ferraro and Jain, 2019). 
2.3.2. Brain metastasis initiation  
Cancer cells that have completed extravasation into the brain, can experience 
three possible fates. They can reach the brain tissue and die due to the 
microenvironment selective pressure, immune surveillance, among other 
pressures (Lambert, Pattabiraman and Weinberg, 2017). Another scenario is that 
after extravasation, the cells become rounded and less proliferative initiating a 
quiescent state termed dormancy (Wells et al., 2013). Finally, after a complete 
extravasation, cancer cells can remain located at the perivascular niche and 




al., 2014, 2018; Wingrove et al., 2019). Previous studies on brain metastasis have 
shown that after arriving to the brain, cancer cells start to become more elongated 
and engage in a cell-cell interaction with brain capillaries in a process called 
vascular co-option. This behaviour of the cancer cells does not involve neo-
angiogenesis and mimics at the molecular and cellular levels the behaviour of 
pericytes. 
 Vascular co-option has been observed in metastasis of multiple different cancer 
origins, such as lung cancer, breast cancer, melanoma, colorectal cancer and 
renal cancer. This process is not exclusive of brain metastasis since it has been 
observed in multiple secondary organs (i.e. lung) (Er et al., 2018). Cancer cells 
engaging in vascular co-option have preferential access to oxygen, nutrients and 
angiocrine factors produced by endothelial cells (Chen et al., 2016; Er et al., 
2018), which gives these cells a survival advantage in a new, hostile 
microenvironment. Only cells which engage in co-option will be able to proliferate 
and form an established brain metastasis (Valiente et al., 2014). 
3. Therapeutic options for brain metastasis 
Nowadays, with the increasing knowledge and new therapies to treat systemic 
disease and with more aggressive treatments and better symptom control, more 
patients have the time to develop brain metastases. Currently, available therapies 
to patients with brain metastasis are very limited and can be divided into local 
and systemic. Local options include surgery and radiotherapy, and systemic 
therapies include chemotherapy, targeted therapies and immunotherapy (Arvold 
et al., 2016). However, treatment to brain metastasis is still mainly palliative. 
Therefore, it is crucial to find new therapeutic modalities in order to decrease the 
neurological defects, increase the quality of life of these patients and their overall 
survival.  
3.1. Surgery 
Surgery is used to obtain tissue for diagnosis in addition to reduce intracerebral 
pressure and to prolong survival by removing the bulk of the tumour (Achrol et 




described as palliative care more than a curative therapy due to moderate impact 
of overall survival of patients.  
To be a good candidate to surgery, brain metastatic patients need to fulfil several 
parameters. The patient should have up to two metastases, should have well-
controlled systemic disease, a good functional status (KPS ≥70), age <65 years 
old, and intact neurological function. The metastasis should be in an area of the 
brain that is surgically accessible with minimal risk of damage, and an absence 
of leptomeningeal infiltration (Arvold et al., 2016). Surgery can be used alone or 
in combination with radiation therapy. Usually, whole brain radiotherapy is used 
as a prophylactic strategy to decrease the risk of local relapse of the tumour after 
debulking of the tumour mass (Arvold et al., 2016). 
3.2. Radiotherapy  
Like surgery, radiation is largely used in brain metastatic patients as a palliative 
treatment, in order to decrease symptoms and improve the patient’s quality of life. 
Historically, radiation has long been used to treat cancer. Radiation treatment can 
induce irreparable DNA damage, with many double-strand breaks, and thereby 
activate DNA damage-dependent apoptotic pathways.   
There are two general types of radiotherapy protocols that are employed in 
patients:  whole brain radiotherapy (WBRT), patients receive a fractionated dose 
of radiation administrated over the entire brain, and stereotactic radiosurgery 
(SRS), which treats only a defined region of the brain usually using a single dose 
of radiation. These protocols can be used alone or in combination with surgery or 
chemotherapy. 
Whole brain radiation therapy (WBRT) is the treatment of choice for patients with 
multiple metastases, which corresponds to more than 60% of patients with brain 
metastasis. This treatment can be used also as a prophylactic adjuvant therapy 
after surgery, in order to prevent local relapse. WBRT has been described as an 
effective treatment for the control of symptoms in 80% of patients with brain 
metastases; however, the effect on overall survival is poor, with an average 




treatment with WBRT increases patients’ risk for developing neurologic deficits 
over time.  
Recent clinical studies have opened the door for a discussion regarding an 
important question:  
Does WBRT really offer meaningful benefits for patients with brain metastases?  
There is significant controversy surrounding this issue; based on these studies, it 
seems that treating patients with WBRT does not increase overall survival or 
quality of life when compared with palliative care alone or stereotactic 
radiosurgery (Mulvenna et al., 2016).  
Stereotactic radiotherapy (SRS) is a modality of radiation therapy used to treat 
small tumours (less than 3cm diameter) in the brain of those patients with a low 
number of lesions on brain (1-3). The location is also an important parameter to 
consider in order to select a patient for this therapeutic modality. This type of 
radiotherapy can deliver precisely radiation only in areas of the brain affected by 
the metastasis. Unfortunately, SRS therapy has also some important issues, first 
of all SRS is a more complex and costly treatment and consequently could be not 
available in all the radiotherapy centres. Besides that SRS compared with WBRT 
are a higher risk of new BrM during follow-up (e.g., distant brain recurrences), 
and an increased risk of radio necrosis (focal damage of the nearby brain tissue 
caused by a high dose of radiation), depending on the volume of healthy brain 
tissue which is irradiated to a relatively high dose, tumour biology factors, and the 
location of the tumour. Important temporary or permanent neurologic symptoms 
could be discerned (Hartgerink et al., 2018).  
The difference between SRS and WBRT permits that a patient could receive in 
one session an amount of radiation (20-27Gy radiation dose) specifically 
delivered to the metastasis while WBRT would require 10 or more sessions and 
without the possibility of avoiding the irradiation of unaffected brain. Thus, less 
adverse effects to the patient are expected. However, studies comparing WBRT 
and SRS have found conflicting results. One study from 2016 showed that 
application of SRS after surgery resulted in better local disease control compared 




randomised clinical trial comparing adjuvant SRS with standard postsurgical 
monitoring replicated this finding (Kocher et al., 2011) and observed a greater 
local control benefit for small resected areas (0-2,5cm) compared to large ones.  
A second randomised trial compared postsurgical WBRT paired with SRS on 
nonresectable tumours to cavity-targeted SRS paired with SRS on nonresectable 
tumours (Marchan et al., 2018). This group found that the use of WBRT led to 
greater neurocognitive deficit than SRS only, and no survival benefit. However, 
they also observed that SRS alone resulted in worse disease control, both locally 
and throughout the brain, compared to WBRT. The poor outcome of SRS only in 
this study could be due to microscopic metastases throughout the brain, which 
are not targeted by adjuvant SRS. In cases where micrometastasis are likely, 
combination of SRS with another treatment modality, such as targeted therapy or 
immunotherapy, might provide better disease control with fewer overlapping side 
effects. Overall, it is important to consider the relative importance of local control, 
whole-brain control, and the risk of neurocognitive deficits all together for each 
individual patient situation when choosing a therapy for brain metastasis.   
In summary, WBRT remains the standard of care for patients with multiple brain 
metastases or a poor functional status. SRS is being implemented in many 
hospitals although is likely that its intrinsic limitation rather that substitute WBRT 
complement it for some patients. 
More experimental studies are necessary in order to increase the efficacy of 
WBRT for the treatment of brain metastasis and to clarify the real profit of using 
this therapeutic option.  
3.3. Chemotherapy 
Chemotherapy is a classical type of systemic therapy used in cancer. In contrast 
to the primary tumour, where chemotherapy can easily reach the cancer cells, in 
the brain there are several factors which prevent the access of this therapy to the 
cancer cells and consequently limit the efficacy. 
The blood brain barrier (BBB), the high interstitial fluid pressures and abnormal 
local perfusion affect the ability to drug delivery to brain metastasis and its 




metastatic cells undergo significant genetic changes after leaving the primary 
tumour until they colonize the brain parenchyma due to diverse selection 
pressures leading to divergent evolution. These genetic alterations could result 
in a metastasis that is non-responsive to a drug despite the manifest sensitivity 
of the primary tumour.  
Although chemotherapy has been used for decades, one of the main caveats is 
that it is not specific. Recent studies have demonstrated the importance of 
developing effective targeted therapies and immunotherapies that are tailored to 
each patient and each lesion, in order to exploit identifiable tumour vulnerabilities 
and boost response rates (Rosenberg, 2014; Melero et al., 2015; Sharp et al., 
2016; Thallinger et al., 2018). 
3.4. Targeted therapy  
Target therapies have been developed for the treatment of specific types of 
cancers with well-defined molecular alterations. Usually patients with brain 
metastasis have been excluded from these studies. However, new clinical trials 
have started to show a potential utility of these agents in patients with brain 
metastasis.   
Some studies showed that EGFR and ALK tyrosine kinase inhibitors (TKIs) have 
good central nervous systems penetration, achieving response rates between 
40% to 80% in EGFR-mutant or ALK-positive non-small-cell lung cancer and an 
increase of 15 to 22 months in overall survival, respectively (Ansari et al., 2009; 
Grommes et al., 2011; Welsh et al., 2013). Additionally, for patients with brain 
metastasis from HER2-positive breast cancer, several clinical trials suggest that 
response rates are better when patients are treated with the combination of 
neratinib (a small molecule that is a dual inhibitor of HER2 and EGFR) and 
capecitabine (a chemotherapeutic agent that inhibits active form of thymidine, 
thymidine monophosphate, which is required for the de novo synthesis of DNA) 
compared to chemotherapy alone (Freedman et al., 2016, 2017). For patients 
with ER-positive or PR-positive breast cancer brain metastasis, preliminary data 
also support the use of selective inhibitors of cell cycle proteins CDK4 and CDK6 




 Targeted therapies have also been studied in patients with brain metastatic 
melanoma with relative success. Some studies have demonstrated an increase 
of response in 20% to 38% in melanoma brain metastasis BRAF-mutant treated 
with BRAF inhibitors like vemurafenib and dabrafenib (Long et al., 2012; Dummer 
et al., 2014; Davies et al., 2017; McArthur et al., 2017). 
Taken together, these data suggest that targeted therapies, possibly in 
combination with chemotherapy or radiotherapy, are a promising treatment 
strategy for brain metastasis. 
3.5. Immunotherapy 
Immunotherapies are a novel therapeutic strategy that recently have begun to be 
explored for the treatment of brain metastatic patients. The use of immunotherapy 
in this setting is now being tested in clinical trials, and some promising results 
have been shown in the treatment of brain metastatic patients with melanoma 
and lung (NSCLC) cancer. Specifically, inhibitors of immune checkpoints 
targeting surface molecules CTL4 and PD-1 as well as anti-PDL1 have been 
applied in brain metastatic patients with promising results (Achrol et al., 
2019;Taggart et al., 2018). Using these new drugs alone was associated with an 
intracranial response rate of 33% in NSCLC and 22% in melanoma with a 
sustained effect in some patients for more than 12 months (Goldberg et al., 2016). 
Additionally, combination therapy with several immunotherapeutic agents or even 
the combination of immunotherapy with radiotherapy has been described as 
providing benefits for patients. For example, the combination of anti-CTL4 and 
anti-PD1 in patients with metastatic melanoma have shown even higher response 
with approaching 60%, than when treated separately (Goldberg et al., 2016). It 
has been also described that the combination of anti-PDL1 with radiotherapy 
(SRS or WBRT) showed a synergism in response rates to dual therapies 
(Anderson et al., 2017; Nardin et al., 2018). However, it has to be noticed that all 
these data correspond to asymptomatic brain metastasis since the rate of 





Besides all these promising preliminary results, the study of the underlying 
biology, molecular mechanisms, and potential side effects of these therapies 
specifically in the brain metastatic setting need to be very carefully evaluated. 
4. Models of brain metastasis  
4.1. Overview of experimental models of brain metastasis 
As previously described in this introduction (see point 1 and 2), the 
formation of brain metastasis is the result of a complex process with several 
steps. This multi-step process that begins with tumour cell invasion, still at the 
primary tumour, and ends with the colonization and establishment of micro and 
macro metastases in brain tissue (Nguyen, Bos and Massague, 2009; Massague, 
Batlle and Gomis, 2017; Valiente et al., 2018; Achrol et al., 2019). Due to the 
complexity of the biology behind brain metastasis it is difficult to fully recapitulate 
all these processes in vitro. In the attempt to improve the ability to mimick the 
metastatic process that occur in brain metastatic patients, new models in vitro, in 
vivo and ex vivo are being used and accepted by the scientific community as a 
fundamental tool to study the different parts of the metastatic cascade and also 
to develop and use models that can give us a holistic view of the process (Bos et 
al., 2009; Nguyen et al., 2009; Li et al., 2013; Sevenich et al., 2014; Valiente et 
al., 2014; Jilaveanu et al., 2015; Martínez-Aranda et al., 2015; Wrage et al., 2015; 
Chen et al., 2016; Priego et al., 2018).  
In order to study brain metastasis, investigators obtained cancer cells from 
patients, usually from pleural fluids or lymph node metastases. These cells were 
engineered with different reporters (e.g. GFP and Luciferase) with the purpose of 
its detection with non-invasive techniques (e.g. bioluminescence) and/or using 
histology or flow cytometry. These cells obtained from patients were used to 
generate new models of brain metastasis by using in vivo selection (Bos et al., 
2009) of the cancer cells that manage to reach the brain, going through the step 
of colonization and developing viable metastasis (Bos et al., 2009; Nguyen et al., 
2009; Valiente et al., 2014; Chen et al., 2016; Priego et al., 2018). These cellular 
models are essential tools for most studies on brain metastasis. Although in vitro 




metastatic cascade, it is an important tool to study for example the passage of 
cancer cells through the BBB, drug screenings, discovery of new mediators of 
metastasis (Bos et al., 2009).  
Preclinical metastatic mouse models are a fundamental tool to develop 
new therapies and approaches to treat the disease. There are several different 
mouse models that can be divided in spontaneous metastatic models, which 
consists on mice genetically engineered, typically with oncogenes that have been 
either down or up-regulated, to induce the disease. The main difficulty of using 
these models is that it takes several weeks to months to generate brain 
metastasis. On the other hand, syngeneic models of brain metastasis are the best 
models to study the crosstalk between tumour cells and host microenvironment, 
including the immune system. In contrast, xenograft models require the use of 
human tumour cells into immunocompromised mice, either in orthotopic (tumour 
is implanted into its natural environment) or heterotopic (tumour is injected into a 
different tissue or organ) locations (Khanna and Hunter, 2005). 
The use of in vivo models to examine brain metastasis is a powerful tool 
for understanding the interactions that occur between the infiltrating tumour cells 
and the resident brain cell population. Together with immunologic, molecular and 
microscopy techniques these models are a very good platform on which 
researchers can recapitulate the metastatic cascade. 
In order to incorporate the highest degree of complexity, patient derived 
xenografts (PDX) models are becoming important to study brain metastasis. The 
use of PDX models could be relevant to evaluate personolized therapies. 
Unfortunately, these models present several caveats, they require 
immunosuppressed hosts and usually they are not easy models to incorporate 
genetic manipulations, thus compromising the monitoring of tumour evolution and 
the identification of the tumour cells on the host tissue by molecular or 
immunological techniques.  
Summing up the develop and use of new models is very important in order 
to increase the identification novel and more effective therapeutics that block the 




4.2. Use of radiotherapy in experimental models of brain metastasis  
Models to study brain metastasis include: In vitro models with brain metastatic 
cell lines, organotypic models from mouse and human brain tissue, xenografts, 
allografts, patient derived xenografts and spontaneous brain metastasis models.  
All these models are important for finding new mechanisms and mediators 
involved in brain metastasis and are also used to test new drugs and therapies. 
Our main interest with this thesis work was to establish new experimental models 
to interrogate radiation resistance in brain metastasis. Previous studies using 
radiotherapy in experimental models of brain metastasis showed a limited 
response of cancer cells to radiation; however, all these studies had 
significant/important limitations and none of them suggested a potential mediator 
or mechanism that could explain the limited response to radiotherapy. Martinez-
Aranda et al. (2013) in a preclinical protocol tested a multifractionated whole brain 
radiation therapy (WBRT) (with three 5,5Gy fractions delivered on consecutive 
days) in association with a chemotherapy agent, temozolomide (TMZ), a known 
chemotherapeutic agent used as a radiosensitizer in primary brain tumors 
(60mg/kg/day orally for five consecutive days) (Martinez-Aranda et al., 2013). 
They observed doubling of survival in mice treated with this combination 
compared to controls. Additionally, Smart et al. (2015) developed a preclinical 
model for radiation therapy of brain metastasis in breast cancer.  In this study, 
mice were randomized to groups receiving WBRT as delivered in the clinic (3Gy 
a day for 10 days) that was compared to another arm only receiving a single dose 
of radiation (Smart et al., 2015). Fractionated radiation impaired the development 
of micrometastasis but failed to affect established brain metastases, which 
correspond to the clinically repevant scenario. 
Finally, Leder et al. (2014) developed and tested a mathematical model of 
fractionated radiotherapy in vivo. They claim that treating at different hours during 
the day and with variable doses during the time of the treatment they will improve 
the effect of radiation in glioma (Leder et al., 2014).  
All published models were important tools as a starting point for our work. 
However, all protocols had limitations. In the Smart et al. protocol, they only saw 




As mentioned before this does not recapitulate the clinical situation since, at the 
time of diagnosis, brain metastases are big enough to be detected with MRI or, 
even worst, they generate neurological alterations. In the work of Leder et al., the 
mathematical model was designed for glioma rather than for brain metastases. 
Finally, considering the Martinez-Aranda et al. study, they did not clarify whether 
the phenotype was due to radiation or chemotherapy since they did not include 
single arms for the monotherapies.  
5. S100A9 
5.1. Molecular characterization 
S100 calcium binding protein A9, also called calgranulin B and Myeloid related 
protein 14 (MRP-14), is a calcium and zinc-binding protein that plays a key role 
in the regulation of inflammatory processes and the immune response. S100A9 
belongs to the S100 family of proteins, which are characterized/defined by 
containing 2 EF-hand calcium-binding motifs.  S100A9 can be found as a 
monomer or as a heterodimer conjugated with S100A8; when conjugated with 
S100A8, it is called calprotectin (Nacken et al., 2003).  
S100A9 is expressed in a wide variety of cells (e.g. epithelial cells, different types 
of cancer cells), but it is in myeloid cells, (i.e. neutrophils, monocytes, 
keratinocytes and early differentiation states of macrophages), where S100A9 
expression is more abundant. It can be found in different cellular compartments 
such as the cytoplasm, cytoskeleton, and plasma membrane, and is also known 
to be secreted (Gebhardt et al., 2006). 
S100A9 protein has been described to be involved in several important molecular 
functions. Intra- and extracellular mechanisms related to inflammation and 
immune response could be trigger for S100A9. S100A9 intracellular functions 
include: proinflammatory (recruitment of leukocytes, promotion of cytokine and 
chemokine production and regulation of leukocyte adhesion and migration), 
leukocyte arachidonic acid trafficking and metabolism, activation of neutrophilic 
NADH-oxidase, modulation of tubulin-dependent cytoskeleton during phagocytes 




also stimulates innate immune cells through binding to TLR4 and RAGE receptor 
and consequently activating the MAP-kinase and NF-kappa-b signalling 
pathways resulting in an exacerbation of the proinflammatory cascade 
(Srikrishna, 2012; Markowitz and Carson, 2013; Leanderson, Liberg and Ivars, 
2015; S. Wang et al., 2018). 
5.2. S100A9 in health and disease  
S100A9 is an important mediator of inflammation and the immune response 
during an infection or another challenge, as described above. However, 
deregulated S100A9 expression has been implicated in different diseases, 
including autoimmune disease, cystic fibrosis (Lorenz et al., 2008; Bargagli et al., 
2011), Crohn’s disease (Pavlidis et al., 2016; Jovanovic et al., 2018), rheumatoid 
arthritis (van Lent et al., 2008; Smith et al., 2017; Nys et al., 2019), chronic 
bronchitis and many types of cancers (Bergenfelz et al., 2015; Lim et al., 2016; 
Nedjadi et al., 2018) and neurodegenerative disorders such as Alzheimer’s 
(Chang, Kim and Suh, 2012; Wang et al., 2014; Gruden et al., 2016). Independent 
studies showed that the upregulation of the S100A9 gene plays an important role 
in the neuropathology and memory impairment in Alzheimer’s disease, 
suggesting that the knockdown and knockout of this gene have a great 
therapeutic potential (Chang, Kim and Suh, 2012; Wang et al., 2014; Gruden et 
al., 2016).Horvath et al. (2016) suggests that S100A9 could be used as a robust 
biomarker to differentiate early stages of cognitive impairment in Alzheimer’s 
disease (Horvath et al., 2016). 
The knowledge about the function of S100A9 in brain metastasis is scarce. Yan 
Liu et al., (2016) identified S100A9 as one of the inflammation mediators 
important in the preparation of the metastatic site and the attraction of cancer 
cells to that site (Liu and Cao, 2016). They describe the action of S100A9 as a 
consequence of the high expression of TNFα that causes a positive loop of 
expression of inflammatory mediators and an increase in the attraction of myeloid 










The main objective of my PhD project was: 
To establish new experimental models to interrogate the underlying biology of 
radiation resistance in brain metastasis and to find potential mediators of this 
process that can be used as biomarkers to predict radiation response in patients 
and/or use these resistance mediators to be targeted with radio-sensitizers.   
In order to do this, we designed specific aims: 
1. Establishment of a brain metastasis model treated with radiotherapy 
(Whole brain radiation therapy, WBRT).  
2. Identification of potential mediators of radiation resistance. 
3. Functional characterization of potential mediators of radiation 
resistance. 
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Material and Methods 
1. Tissue Culture 
1.1. Cell Culture 
 Adherent cells 
Human (H2030-BrM3, MDA231-BrM2, PC9-BrM3) and mouse (ErbB2-BrM2, 
393N1, 482N1) brain metastatic cell lines were previously described (Bos et al., 
2009; Nguyen et al., 2009). MDA231-BrM2 (abbreviated as MDA231-BrM), 
ErbB2-BrM2 (abbreviated as ErbB2-BrM), 393N1, and 482N1 cells were cultured 
in DMEM media supplemented with 10% foetal bovine serum (FBS), 2 mM L-
Glutamine, 100IU/ml penicillin/streptomycin and 1 mg/ml amphotericin B. H2030-
BrM3 (abbreviated as H2030-BrM), PC9-BrM3 (abbreviated as PC9-BrM) and 
HCC1954-BrM1 (abbreviated as Hcc1954-BrM) were cultured in RPMI1640 
media supplemented with 10% FBS, 2 mM L-Glutamine, 100IU/ml 
penicillin/streptomycin, and 1 mg/ml amphotericin B. 293T cells were cultured in 
DMEM media supplemented with 10% FBS, 2 mM L-Glutamine, 100 IU/ml 
penicillin/streptomycin, and 1 mg/ml amphotericin B. 
 Brain metastasis model E0771-BrM 
To generate a new brain metastatic model, E0771-P (parental) cells were 
administered via intracardiac injection to obtain brain metastatic derivatives. 
Briefly, a cell suspension containing 105 E0771-P cells expressing a Luciferase 
construct (Addgene ref. 19166), in a volume of 100μl were injected in the left 
cardiac ventricle of anaesthetized 4–6-week-old C57BL/6 mice. Tumour 
development was monitored by bioluminescence imaging using the IVIS-200 
imaging system every three days. Brain lesions were localized by ex vivo 
bioluminescence imaging (BLI) and resected under sterile conditions. Tissue was 
minced and placed in a culture medium containing a DMEM supplemented with 
0.125% collagenase III and 0.1% hyaluronidase. Samples were incubated at 37° 
C for 1 h, with gentle rocking. After collagenase treatment, cells were briefly 
centrifuged, resuspended in 0.25% trypsin, and incubated at 37° C for 15 min. 
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Cells were resuspended in culture media and allowed to grow to confluence on a 
10 cm dish. Two additional rounds of in vivo selection were performed.  
Brain metastatic cells, E0771-BrM3 (abbreviated as E0771-BrM), transduced 
with a lentiviral vector encoding ZsGFP (Catalog No. 632179, Clontech) and 
sorted for further propagation in culture or inoculation in mice. E0771-BrM was 
cultured in RPMI1640 media supplemented with 10% FBS, 1% Hepes 1M, 2 mM 
L-Glutamine, 100IU/ml penicillin/streptomycin, and 1 mg/ml amphotericin B.  
1.1.3. Mouse glial cell culture 
Mouse glial cells were obtained from one to three-day old mice pups (Schildge et 
al., 2013). In brief, brains were mechanically dissociated and filtered through 100 
mm filters. The resulting cell suspension was cultured in a petri dish for 7 days in 
DMEM media supplemented with 10% FBS and 2nM L-Glutamine. Cells that 
survive the culture period are predominantly astrocytes, microglia and 
oligodendrocytes. 
1.1.4. Oncosphere assay 
Brain metastatic cell lines (H2030-BrM, E0771-BrM and 482N1), were plated in 
low-attachment plates with a density of 1x103 cells per well in Humec (Gibco, ref: 
12753018) medium supplemented with basic human fibroblast growth factor 
(bFGF, 10ng/mL, Gibco, ref: 13256-029), Epidermal growth factor (EGF, 
20ng/mL, Sigma-Aldrich, ref:E9644), insulin solution from bovine pancreas 
(Sigma, 5ug/mL, ref:I0516), and B27 supplement (Gibco, 1x, ref: 17500-044). 
H2030-BrM and 482N1 cells were culture for 7 days on these conditions in order 
to form isolated oncospheres. E0771-BrM cells needed 4 days of culture to form 
equivalent (same size and number approximately) oncospheres to the others cell 
lines studied. When indicated, oncospheres were irradiated at 10Gy in a single 
dose (irradiator Mark I 30A, JLShepherd). 
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1.1.5. Co-culture assays 
1.1.5.1. Co-cultures with insert 
We performed co-cultures using a commercial cell culture insert (High density, 
translucent PET membrane 24 well 0,4μm pore size, Falcon, ref:353495). We 
plated 1,5X104 H2030-BrM cells in the lower chamber of the plate and 4,5x104 
primary glial cells on top of the insert with RPMI1640 media supplemented with 
0,25% FBS, 2 mM L-Glutamine, 100IU/ml penicillin/streptomycin, and 1 mg/ml 
amphotericin B. Co-cultures were irradiated 18h after plating and the results were 
measured 72h after irradiation. 
1.1.5.2. Co-cultures without insert involving cell-cell contact 
In a 24 well-plate, 1,5X104 H2030-BrM cells and 4,5x104 glial cells were plated 
within the same well. The cell mixture was cultured with RPMI1640 media 
supplemented with 0,25% FBS, 2 mM L-Glutamine, 100IU/ml 
penicillin/streptomycin, and 1 mg/ml amphotericin B. Cultures were irradiated 18h 
after culture and the results were measured 72h after irradiation. 
1.1.6. Organotypic cultures 
1.1.6.1. Initiation of metastasis 
Organotypic slice cultures from adult mouse brains were prepared as previously 
described (Valiente et al., 2014). In brief, brains were dissected in Hank’s 
balanced salt solution (HBSS) supplemented with HEPES (pH 7.4, 2.5 mM), D-
glucose (30 mM), CaCl2 (1 mM), MgSO4 (1 mM), and NaHCO3 (4 mM), and 
embedded in low-melting agarose (Lonza) preheated to 42°C. The embedded 
brains were cut into 250 μm slices using a vibratome (Leica). Slices were divided 
at the hemisphere into two pieces. Brain slices were placed with flat spatulas on 
top of 0.8 μm pore membranes (Millipore) floating on culture media (Dulbecco’s 
modified Eagle’s medium [DMEM], supplemented HBSS, 5% FBS, L-glutamine 
(1 mM), 100 IU/ml penicillin, 100 mg/ml streptomycin). 3x104 cancer cells 
resuspended in 2 μl of culture media were placed on the surface of the slices and 
incubated for 3 days.  
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1.1.6.2. Established metastasis 
Brains with established metastasis were obtained at the experimental endpoint 
(5-7 weeks in human BrM cell lines, 2 weeks in mouse BrM cell lines). The 
methodology to generate the organotypic culture was the same as described 
above however without the need of plating the cancer cells since they are already 
within the tissue. Brain slices were imaged to confirm the presence of established 
metastases using BLI. 
1.2. In vivo and ex vivo therapy  
1.2.1. Radiation treatment assay 
All cell types and organotypic cultures that were subjected to radiation received 
a single dose of 10Gy of gamma radiation (irradiator Mark I 30A, JLShepherd); 
source used was Cs-137 (662 KeV E.max).   
BLI was acquired 18 hours after plating cancer cells (Day 0) and brain slices were 
irradiated immediately after that with 10Gy radiation dose. Subsequently, BLI was 
acquired again 3 days after radiation (Day 3). The growth rate was obtained by 
comparing bioluminescence fold increase between day 3 and day 0.  
1.2.2. Drug treatment assay 
FPS-ZM1 inhibitor (10uM, Selleck chemicals, cat. S8185) or Bay11-7082 inhibitor 
(50uM, Selleck Chemicals, cat. S2913) were administered once during the 
experiment at the same time that the cancer cells were plated on the surface of 
brain slices or when established metastases were placed on the culture 
membrane, by adding it directly into the media.  A BrdU pulse (0.2 mg/ml, Sigma-
Aldrich, ref. B9285) was given by adding it in the media four hours before fixing 
brain slices in paraformaldehyde (4%) overnight. Free-floating 
immunofluorescence was performed afterwards and mounted with Mowiol-Dabco 
anti-fade reagent. 
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 In Vivo analysis: 
2.1. Procedures on animals  
All animal experiments were performed in accordance to a protocol approved by 
the CNIO, Instituto de Salud Carlos III and Comunidad de Madrid Institutional 
Animal Care and Use Committee. Athymic nu/nu (ENVIGO), and C57BL/6 mice 
4–6 weeks of age were used. A brain metastatic derivative of the syngeneic 
E0771 model (E0771-BrM3) was established according to a previous protocol 
(Bos et al., 2009; Nguyen et al., 2009). For intracardiac models of brain 
colonization, 100 μl of PBS containing 100,000 cancer cells was injected into the 
left ventricle. Alternatively, 2 μl of PBS containing 25,000 cancer cells was 
intracranially injected (right frontal cortex, approximately 1.5 mm lateral and 1 mm 
caudal to the bregma, and to a depth of 2 mm) using a gas-tight Hamilton syringe 
and a stereotactic apparatus. Brain colonization was analysed in vivo and ex vivo 
by bioluminescence imaging. Briefly, mice were anesthetized using 3% 
isoflurane, injected retro-orbitally with D-Luciferin (150 mg/kg) and imaged with 
an IVIS Spectrum Xenogen machine (Caliper Life Sciences). Bioluminescence 
analysis was performed using Living Image software, version 3.  
To study the radiation response of BrM cells injected subcutaneously in the head 
of the animal, 5x105 cells were resuspended in 100uL PBS mixed with 50% 
reduced growth factor Matrigel (Corning Matrigel growth factor) and injected 
subcutaneously.  
2.1.1. Radiation therapy protocols In vivo 
The irradiator Mark I 30A (J.L. Shepherd & Associates, USA) system was used 
for irradiation of mice. Cranial irradiation was delivered using an opposed lateral-
beam geometry, collimated to produce a 0.5 cm diameter field at the depth of 
interest. The body was protected by a 3 cm custom-made shield device that 
covers the mice except for the head.  
The source used in this case was Cs-137 (662 KeV E.max). The source-to-axis 
distance was 20 cm, and the collimator-surface distance was 7 cm. Doses 
ranging between 2,0 and 5,5 Gy were delivered at a dose-rate of 1,54 Gy/min. 
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Activity at calibration date was 1100 Ci (10/10/2002). Calibration was performed 
by manufacturer (J.L. Shepherd & Associates, USA) following internal procedure 
using an MHS Industries Model 2025 x-ray monitor (S.N. 4212) with a 0.18cc 
probe (S.N. 8716-5), and converter (S.N. 8730). This meter is calibrated by J.L. 
Shepherd & Associates Cs-137 Model 89 calibration range (S.N. 8190), by use 
of N.I.S.T. Transfer dosimeters, National Institute of Standards and Technology 
Report #DB917/114, dated March 20, 1996. 
The animal was placed in a methacrylate chamber and anesthetized using 
ketamine/xylazine as described below. None of the immobilization devices were 
in the beam path. The doses were not corrected for surface curvature or tissue 
heterogeneities. Dosimetry standardization was adequate for reliability and 
reproducibility of our findings. 
Radiation protocol A: Based on Leder et al., who reported an optimized protocol 
for radiation therapy in glioblastoma patients (“Optimum-2”). Radiation schedule 
was as follows: Day1: Dose: 3Gy/ Time: 8am; Day2: Dose: 1Gy/ Time: 4pm; 
Day3: no radiation; Day4: Dose: three of 1Gy/ Time: 9am, 1pm, 5pm; Day5: Dose: 
three of 1Gy/ Time: 9am, 1pm, 5pm (Leder et al., 2014). 
Radiation protocol B: Based on a protocol established by Martinez-Aranda et al. 
who applied a chemoradiation protocol with Temozolomide (TMZ, Oral gavage, 
60 mg/kg/day, for 5 consecutive days) on mouse models of brain metastasis. In 
our experiments, radiation was administered only to the head of the mouse. 
Radiation schedule was as follows: Day1: Radiation: Dose: 5,5Gy; Day2: 
Radiation: Dose: 5,5Gy; Day3: Radiation: Dose: 5,5Gy. Total radiation dose per 
mouse was 16,5Gy (Martinez-Aranda et al., 2013). 
Radiation protocol C: Based on the Smart et al. radiation protocol for brain 
metastasis. Radiation schedule was as follows: 3Gy for five days, two days 
without radiation and 3Gy for five additional days. Total dose per mouse was 
30Gy (Smart et al., 2015).  
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3. Tissue analysis: 
3.1. Immunofluorescence 
Slicing of whole brains was done using a vibratome, in case of fresh samples 
(Leica VT1000S), or sliding microtome (Thermofisher HM450), in case of fixed 
samples. Brain tissues sectioned by vibratome were later fixed in 4% PFA at 4º 
C. Brains to be sectioned with the microtome were initially fixed in 4% PFA at 4º 
C overnight and then  dehydrated in sucrose 15% overnight and finally 
maintained in sucrose 30% until be sectioned. 
Both types of brain slices (250 μm, vibratome, and 80 μm, microtome) were 
blocked in NGS 10%/BSA 2%/Triton 0.25% in PBS for 2 hr at room temperature 
(RT). Primary antibodies were incubated overnight at 4ºC in the blocking solution 
and the following day for 30 min at RT. After extensive washing in PBS-Triton 
0.25%, the secondary antibody was added in the blocking solution and incubated 
for 2 hr at RT. After extensive washing in PBS-Triton 0.25%, nuclei were stained 
with bisbenzimide (1 mg/ml; Sigma) for 7 min at RT. The same protocol was 
applied to stain oncospheres. 
Table 2. Antibodies list 
Primary antibodies 
• Anti-Green Fluorescent Protein (Aves Labs, ref. GFP-1020, dilution 1:1,000)  
• Anti-BrdU (Abcam, ref. ab6326, dilution 1:500),  
• Anti-S100A9 anti-human (Dako, ref. M747, dilution 1:200),  
• Anti-s100a9 anti-mouse (Cell Signalling, ref: #73425, dilution 1:100),  
• Anti-phospho-histone H2ax (Ser139) anti-human (Millipore, cat. #05-636, dilution 
1:1000) 
Secondary antibodies* 
• Alexa-Fluor plus Goat anti-chicken488, (cat. #A11039) 
• Alexa-Fluor plus Goat anti-rabbit555 (cat. #A21429) 
• Alexa-Fluor plus Goat anti-mouse555 (cat. #A21422) 
• Alexa-Fluor plus Rabbit anti-mouse633 (cat. #A21072) 
• Alexa-Fluor plus Goat anti-mouse647 (cat. #A21236) 
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*All the secondary antibodies  are from Invitrogen. We use a work dilution of 
1:300 in all of them except for Alexa Fluor anti-chicken 488 with a dilution of 
1:500.  
3.2. Immunohistochemistry 
A total of twenty-six human brain metastasis samples from lung cancer or breast 
cancer were obtained from the Soffietti lab (University Hospital Turin) (16 
samples) and the Cohan-Jonathan Moyal lab (Institute du Cancer Toulouse) (10 
samples). Immunohistochemistry (IHC) was performed at the CNIO 
Histopathology Core Facility using standardized automated protocols. Single 
immunohistochemistry (Autostainer Link, Dako or Ventana Discovery XT, Roche) 
was initiated by performing antigen retrieval with high or low pH buffer (depending 
on the primary antibody) and, after blocking of endogenous peroxidase (3% 
hydrogen peroxide), slides were incubated with the appropriate primary antibody, 
mouse monoclonal anti-S100A8/S100A9 (Myeloid/Histocyte Antigen, MAC 387, 
RTU, Dako, M0747). After the primary antibody, slides were incubated with the 
corresponding secondary antibodies and visualization systems when needed 
(EnVision FLEX+, Dako) conjugated with horseradish peroxidase. The 
immunohistochemical reaction was developed using 3,3-diaminobenzidine 
tetrahydrochloride (DAB). Nuclei were counterstained with Carazzi’s 
haematoxylin. Finally, the slides were dehydrated, cleared and mounted with a 
permanent mounting medium for microscopic analysis. Expression of S100A9 in 
metastatic cells and in the microenvironment was independently evaluated and 
scored as 0, 1, 2 or 3 (no expression of S100A9, low-, intermediate-, and high-
expression of S100a9, respectively) by clinical neuropathologists. 
3.3. Image acquisition and analysis 
Images were acquired with a TCS-SP5-X laser scanning confocal microscope 
(Leica-Microsystems) equipped with AOBS, a tuneable white light laser, a 
10X/0.4NA and a 20X/0.7NA dry lenses, a 20X0.7NA multi-immersion lens, a 
40X/1.25NA and 63X/1.4NA oil immersion lenses, and LAS AF software. Mosaic 
images of the oncospheres were imaged with a DM6000I workstation (Leica-
Microsystems) equipped with a 5X/0.15NA (numerical aperture) dry lens, and 
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LAS AF and Leica HCS software. Acquired images were analysed with ImageJ 
software and Definiens developer XD 2.5. 
3.4. Bioluminescent acquisition and analysis  
3.4.1. In vitro and ex vivo assays 
Bioluminescence images were taken using an IVIS Spectrum (Perkin Elmer, 
Waltham MA). Five minutes before imaging BrM cells in vitro and brain slices ex 
vivo, 20uL/mL of D-Luciferin (15mg/mL, Caliper Life Sciences, part number 
#119222) was added to the media 
3.4.2. In vivo 
For in vivo imaging, mice were anesthetized with 3% isoflurane gas anaesthesia 
and then injected retro-orbitally with 100 µL of 15 mg/mL D-luciferin stock 
solution. After the D-luciferin injection, the animals were placed on the stage of 
the IVIS Spectrum in a prone position with the animal's dorsal side facing the 
CCD camera. Default bioluminescent settings of Living Image 4.0 were used. 
Regions of interest (ROI) were drawn on the 2D bioluminescent image over the 
brain metastasis lesions and total photons emitted were calculated. The image 
analysis and quantification were done using Living Image 4.0 software and the 
luminescence was reported in photon flux. 
4. Flow-cytometry 
4.1. Sorting 
Brain metastatic cells were detached using trypsin (Gibco, ref: 25300-054). The 
cell pellet was resuspended in RPMI media supplemented with 0,25% FBS, 2 
mM L-Glutamine, 100IU/ml penicillin/streptomycin and 1 mg/ml amphotericin B, 
at a final concentration of 5-10x106 cells/mL. Before sorting, cells were filtered in 
a 50um sterile filter (Sysmex, ref:04-004-2327) and 2uL/mL of DAPI solution 
(stock solution 200ug/mL; Sigma, ref: D9542) was added. Sorted cells were 
collected in RPMI media supplemented with 10% FBS, 2 mM L-Glutamine, 
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100IU/ml penicillin/streptomycin and 1 mg/ml amphotericin B, centrifuged, and 
plated in a 10 cm dish with fresh culture media. 
All sorting steps were conducted using an Influx cell sorter (BD, San Jose CA) 
with a nozzle of 100um. E0771-BrM cells were selected based on expression of 
green fluorescent protein (GFP). H2030-BrM were isolated from the co-culture 
with glial cells based on GFP+ expression as well. 
To clarify whether NFκβ is activated by S100A9 and if this pathway is the 
responsible for the radiation resistance phenotype, we infected BrM cells with a 
lentivirus containing a NFκβ reporter (cdc-5NF-mCherry) and a colour marker 
(mCherry) (Badr et al., 2009). 
 In order to select the cells infected by the lentivirus with the NFκβ reporter vector, 
H2030-BrM mCherry positive BrM cells were treated with recombinant human 
TNFα (cat: 300-01A, Peprotech), an activator of NFκβ pathway, for 28h to then 
sort out the mCherry+.  
5. Molecular analysis: 
5.1. Transcriptomic analysis 
5.1.1. Real-time quantitative PCR (qRT-PCR) 
Whole RNA was isolated using an RNAeasy Mini Kit (QIAGEN). 1000 ng RNA 
was used to synthesize cDNA using an iScript cDNA Synthesis Kit (Bio-Rad, ref. 
1708890). RNA obtained from mouse brains included micro-dissected 
established metastases from human BrM cells. In these cases, the 
microenvironment was analysed using mouse primers, while human primers 
were utilized to analyse the cancer cells. RNA from BrM cell lines was obtained 
from a confluent well of a 6-well plate. RNA from oncospheres was obtained from 
cells cultured in low attachment 24-well plates or 10 cm plates. Quantitative PCR 
(qPCR) reactions were conducted using SYBR green gene expression assays 
(GoTaq® qPCR Master Mix Promega, ref. A6002). qPCR reaction was performed 
on QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) and 
analysed using QuantStudio 6 and 7 Flex Software. 




Table 3. Primers used for human genes (5´->3´): 
Gene  Forward Reverse 
S100A9 TGGAACGCAACATAGAGACCA CGCCATCAGCATGATGAACT 
TNFα CGAGTGACAAGCCTGTAGC GGTGTGGGTGAGGAGCACAT 
TNFR1 CGCTACCAACGGTGGAAGTC CAAGCTCCCCCTCTTTTTCAG 
TNFR2 CAAGCCAGCTCCACAATGG TGACCGAAAGGCACATTCCT 
RAGE GCAGTCGGAGCTAATGGTGA TCCACCACCAATTGGACCTC 
TLR2 GCCAAAGTCTTGATTGATTGG TTGAAGTTCTCCAGCTCCTG 
TLR4 GGTCAGACGGTGATAGCGAG GGGAGGTTGTCGGGGATTTT 
 
Table 4. Primers used for mouse genes (5´->3’): 
Gene  Forward Reverse 
s100a9 CACAGTTGGCAACCTTTATG CAGCTGATTGTCCTGGTTTG 
Tnfα AGGGATGAGAAGTTCCCAAATG GCTTGTCACTCGAATTTTGAGAAG 
 
Relative gene expression was normalized to Beta 2 Microglobulin (B2M - human) 
or beta 2 microglobulin (b2m - mouse) using the primers below: 
 
Table 5. Human genes (5´->3´, forward; reverse): 
Gene Forward Reverse 
B2M  AGATGAGTATGCCTGCCGTG TCATCCAATCCAAATGCGGC 
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Table 6. Mouse genes (5´->3´): 
Gene  Forward Reverse 
b2m GACCGGCCTGTATGCTATCC CAGTAGACGGTCTTGGGCTC 
5.1.2. RNAseq 
Total RNA was extracted using a RNeasy kit (QIAGEN). Cells were lysed with 
RLT + 1% β-mercapto-ethanol (RNAeasy kit, Quiagen). RNA integrity numbers 
ranged from 7.6 to 9.4 (average 8.7) when assayed on an Agilent 2100 
Bioanalyzer. The PolyA+ fraction was purified and randomly fragmented, 
converted to double stranded cDNA, and processed through subsequent 
enzymatic treatments of end-repair, dA-tailing, and ligation to adapters as in 
Illumina's "TruSeq Stranded mRNA Sample Preparation Part # 15031047 Rev. 
D" kit (this kit incorporates dUTP during 2nd strand cDNA synthesis, which 
implies that only the cDNA strand generated during 1st strand synthesis is 
eventually sequenced). An adapter-ligated library was completed by PCR with 
Illumina PE primers (9 cycles). The resulting purified cDNA library was applied to 
an Illumina flow cell for cluster generation and sequenced on HiSeq2500 
(Illumina) following the manufacturer's protocols. Image analysis, per-cycle base 
calling and quality score assignment were performed with Illumina Real Time 
Analysis software. Conversion of Illumina BCL files to bam format was performed 
using Illumina2bam. Single read sequences were analysed by Nextpresso 
pipeline (Grana et al. 2016). Sequencing quality was analysed with FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/); reads were aligned 
to the human genome (GRCh37/hg19) using TopHat-2.0.10 (Kim et al., 2013), 
Bowtie 1.0.0 (Langmead and Salzberg, 2012) and Samtools 0.1.19.0 (Li et al., 
2009); and transcripts assembly, abundances estimation and differential 
expression were calculated with Cufflinks 2.2.1 (Trapnell et al., 2010). The 
estimated significance level (P value) was corrected to account for multiple 
hypotheses testing using a Benjamin and Hochberg False Discovery Rate (FDR) 
adjustment. Genes with FDR less than or equal to 0.05 were selected as 
differentially expressed. PCA plots, hierarchical clustering (Pearson’s 
Dissimilarity), and heatmaps were generated in R and Partek. 
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5.1.3. Gene set enrichment analysis 
Gene set enrichment analysis (GSEA) of differentially expressed genes was 
performed using the GSEA software, Version 2.0.6, obtained from the Broad 
Institute (Subramanian et al., 2005). GSEA was performed to analyse the 
enrichment of gene sets following the developer’s protocol and using pathway 
annotations from the Gene Ontology, Reactome, Biocarta and Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) databases.  
All previously obtained differentially expressed genes were ranked according to 
their t-statistic. This ranked file was used as input for the enrichment analysis. All 
basic and advanced fields were set to default and only gene sets significantly 
enriched at a False Discovery Rate (FDR) q-value < 0,25 were considered. 
5.1.4. Gene Ontology Molecular function 
Gene Ontology analysis was performed using the EnrichR software. 
5.1.5. Loss of function approaches 
5.1.5.1. Lentivirus production and cancer cell infection 
In order to generate stable knockdown cell lines lacking expression of S100A9, 
two different short hairpin RNAs were employed. For human cells, TRC lentiviral 
Human S100a9 shRNA (ref: RHS4533-EG6280, Dharmacon), was utilized, and 
for mouse cell lines, TRC lentiviral Mouse S100a9 shRNA (ref: RMM4534-
EG20202, Dharmacon) was used. Both lentiviral plasmids carry a puromycin 
resistance gene.  
Lentivirus was produced in HEK293T cells grown to 50-70% confluence on the 
day of transfection. The transfection was conducted using 8,75ug of TRC 
lentiviral shRNA (mouse or human) mixed with VSVG, RRE and REV packaging 
vectors in a 1:1 ratio as per manufacturer’s protocol. The lentiviral and packaging 
vectors were mixed in 105uL of lipofectamine transfection reagent (Lipofectamine 
2000 ref: 11668-030, Invitrogen) and 5mL Opti-Mem (ref: 31985-070, Gibco), 
then added to a final volume of 15mL transfection media (Tfm; DMEM, FBS 
11,4%, Glutamine 1%, Sodium Pyruvate 1%) and incubated overnight. To 
Material and Methods 
 
68 
enhance the efficiency of infection, cells were treated with polybrene (1ug/mL; 
Sigma Aldrich). On the day after transfection, the media was changed to fresh 
transfection media and cells were incubated for 36h under standard growth 
conditions.  
Following infection, cells were selected using 2mg/mL puromycin (Sigma 
Aldrich). After three days treated with puromycin all the control cells were dead. 
Selected cells were maintained in culture with a supplement of puromycin in the 
media for two weeks after selection.  
6. Statistical analysis 
Data are represented as the mean values ± S.E.M. When comparisons were 
done between two experimental groups, an unpaired Student's t test was used. 
Overall survival was calculated using Kaplan–Meier survival curves. For survival 
curves, P values were obtained with log rank (Mantel-Cox) test. Heatmaps were 









































1. Establishment of a new breast cancer model to study brain metastasis 
There are a limited number of experimental models that allow studying brain 
metastasis in an immunocompetent background (Valiente et al., 2018), and 
recent work has suggested that the immune system is important for the radiation 
response (Twyman-Saint Victor et al., 2015). Thus, immunocompetent models 
are necessary to investigate the potential mechanisms involved in the response 
to radiation. Taking advantage of the ability of E0771, a well-characterized 
syngeneic breast cancer cell line, to be used in an immunocompetent setting, we 
established a model of breast cancer brain metastasis.  
We performed intracardiac (IC) injection of E0771 parental cell line (E0771-P), a 
basal triple negative breast cancer cell line (Johnstone et al., 2015), that we 
initially engineered to express a plasmid encoding the enzyme luciferase in a 
group of 10 C57BL/6 mice. Expression of luciferase allows non-invasive tracking 
of metastasis progression with bioluminescence imaging (BLI). Seven days after 
IC injection, we started to detect bioluminescence in different regions of the body, 
including lumbar region, abdomen, and head. At day 15 after IC injection, mice 
were sacrificed based on evident worsening of the general health status or weight 
loss equal to or greater than 20%. Ex vivo BLI confirmed extensive metastatic 
load in multiple organs, such as the lung, lymph nodes, and liver. Brain 
metastases were only detected in 2/10 mice, in contrast to lung metastases, 
which were detected in 10/10 mice. Consequently, the E0771-P cell line is highly 
metastatic to multiple organs but has limited ability to colonize the brain, as 
previously reported (Contreras-Zarate et al., 2019).  
To increase tropism to the brain, we dissected the brain metastasis with the 
highest ex vivo bioluminescence value (9x103 average radiance (p/s/cm2/sr). The 
dissected lesion was then enzymatically dissociated in the appropriate media 
(see Methods) and the cancer cells were isolated and cultured in vitro. After two 
passages in vitro, adherent cells were tested with BLI. When bioluminescence 




metastatic). Two additional rounds of in vivo selection (Bos et al., 2009; Nguyen 
et al., 2009) generated the E0771-BrM3 cell line. The new cell line was then 
transfected with a plasmid encoding for ZsGFP (Catalog No. 632179, Clontech), 
which helps to identify cancer cells by means of histology. In order to confirm the 
increased brain tropism of E0771-BrM3 cells compared to the parental 
counterpart (E0771-P), we performed a final experiment in vivo injecting 10 mice 
with each cell line. Fifteen days after IC injection, in vivo bioluminescence signal 
in the head was detectable at higher levels in those injected with E0771-BrM3 
cells (2x105 average radiance (p/s/cm2/sr) compared to those inoculated with 
E0771-P (5x104 average radiance (p/s/cm2/sr) (Figure 1A). Analysis of ex vivo 
brain bioluminescence confirmed a significant increase in brain metastatic burden 
in those animals injected with E0771-BrM3 cells compared with the group of mice 
injected with E0771-P (Figure 1B). In contrast, we did not observe any significant 
difference in extracranial metastasis (Figure 1C), which could explain the lack of 
any difference in survival (Figure 1D) (P= 0,1149). The new model E0771-BrM3 
is identified as E0771-BrM in the rest of the text for simplicity. This model has 
been incorporated to the broad repository of experimental brain metastatic cell 




Figure 1. A new syngeneic breast cancer model to study brain metastasis. 
 
Figure 1. A. Bioluminescence images in vivo and ex vivo at day 15 after 
intracardiac injection. B. Quantification of ex vivo bioluminescence of brains 
comparing E0771-P with E0771-BrM3 (E0771-P n=7, E0771-BrM3 n=13; P= 
0.024). C.  Ex vivo bioluminescence from thoracic and abdominal cavities at day 
15 show no differences between E0771-P and E0771-BrM3 cells. D. Overall 
survival graph comparing mice injected with E0771-P and E0771-BrM3 
cells (Parental n =4, BrM3 n=5, P=0.1149).  
2. Sensitivity of brain metastatic cells to radiation in vitro 
We analysed the efficacy of radiotherapy to impair the viability of brain metastatic 
(BrM) cell lines. Specifically, we tested lung cancer BrM (H2030-BrM; PC9-BrM; 
393N1; 482N1) and breast cancer BrM (MDA231-BrM; CN34-BrM; ErbB2-BrM; 
Hcc1954-BrM1a; Hcc1954-BrM1b; E0771-BrM) models. These models include 




MDA231-BrM; CN34-BrM, ErbB2-BrM, Hcc1954-BrM1a; Hcc1954-BrM1b) cell 
lines (Figure 2C) and represent clinically relevant oncogenomic profiles for each 
tumour type (data not shown).  
We cultured each BrM cell line in vitro under normal culture conditions and 
divided them in two experimental groups, a non-irradiated control group and 
another group that received a single dose of radiation (10Gy of gamma radiation 
(-IR) (Figure 2A). Seventy-two hours later, cells were fixed and stained with 
DAPI. Five different fields from three coverslips per cell line and condition were 
imaged using a fluorescence microscope and quantified for the percentage of 
viable cells (Figure 2B). All models tested presented high sensitivity to radiation, 
which decreased the percentage of viable cells by 45- 83%, depending on the 
model (Figure 2C).   
These results prove that BrM cells lines present a high sensitivity to radiation in 
vitro independently of their species, tissue of origin, or oncogenomic profile. 
Figure 2. Experimental brain metastases are highly sensitive to radiation in vitro.  
 
Figure 2. A. Schema of experimental design. B. Representative images of control 
and irradiated cells (single dose of 10Gy) of H2030-BrM in adherent culture 
conditions. Staining with DAPI. C. Heatmap depicting the percentage of DAPI+ 
cells in the coverslip  (H2030-BrM = 75%, P= 0.002; PC9-BrM= 58%, P= 0.026; 
393N1= 72%, P= 0.02; 482N1= 72%, P= 0.015; MDA231-BrM= 70%, P= 0.011; 
CN34-BrM= 52%, P= 0.007; ErbB2-BrM= 76%, P= 0.012; Hcc1954-BrM1a= 45%, 




3. Sensitivity of Brain metastasis cells to radiation in vivo 
3.1. Human lung adenocarcinoma in an immunodeficient mice model 
(Athymic Nude-Foxn1nu) 
To determine whether the sensitivity to radiation we observed in vitro is 
recapitulated in vivo, we tested several radiotherapy protocols on mice with brain 
metastatic tumours. We chose H2030-BrM, a human lung adenocarcinoma cell 
line, since it was among the most radiosensitive in vitro. 
In order to generate established metastases in the brain, we performed IC 
injection of 1x105 cancer cells per mouse (Nguyen et al., 2009). Given the human 
origin of the H2030-BrM lung adenocarcinoma model, we used immunodeficient 
mice (Athymic Nude-Foxn1nu). 
Fourteen days after IC injection we confirmed the presence of established brain 
metastases by BLI (Figure 3A), defined as heads with photon flux values >104 
(measured as p/s/cm2/sr). In fact, average value was 1,84x105 at the time the 
radiation protocols were initiated (Figure 3B), thus, mimicking very closely the 
clinical situation where fully established metastases are treated. We applied three 
different radiation protocols previously reported in experimental brain tumours 
(Martinez-Aranda et al., 2013; Leder et al., 2014; Smart et al., 2015). To avoid 
extracranial radiotoxicity, we designed and validated a lead metal shield that 
allowed us to irradiate only the heads of mice (Figure 3A and C).  To perform the 
experiment, we divided the animals into four different treatment groups:  Group 
1. Non-irradiated control group, n= 14 mice; Group 2. Irradiated group with 
protocol A (Leder et al., 2014), n= 20 mice; Group 3. Mice subjected to protocol 
B (Martinez-Aranda et al., 2013), n= 7 mice; Group 4. Mice subjected to protocol 
C (Smart et al., 2015), n= 5 mice. Although the details of each protocol can be 
found in the Methods section, they are briefly summarized here.  
Protocol A: mice were treated with a fractionated dose of 1Gy and 3Gy over five 
days. Total dose of 10 Gy per mouse (Leder et al., 2014) . 
Protocol B: mice received a fractionated dose of 5,5Gy/day for 3 days. Total dose 




Protocol C: mice received a fractionated dose of 3Gy/day of radiation dose for 10 
days, reaching a total amount of 30Gy per mouse. Protocol C is the closest to the 
clinical standard of care (Smart et al., 2015).   
Surprisingly, no impact of radiation on brain metastasis progression scored by 
non-invasive BLI could be detected with any of the protocols used (Figure 3D). 
Consequently, mice succumb to the disease at the same time than the non-
irradiated group (Figure 3E). BLI analysis showed that there was no difference in 
terms of the BLI signal in the different groups of irradiated mice compared with 
the non-irradiated group (Figure 3D). In terms of overall survival, we observed no 
difference between any of the treatment groups. All of the animals died between 
day 21 and day 55 after IC (Figure 3E). 
These results suggest that, in contrast to what we observed in vitro, radiation 




Figure 3. In vivo response to radiation in immunodeficient mice.   
 
Figure 3. A. Schema of experimental design. B. Bioluminescence representative 
image at day 14 after intracardiac injection. C. Schematic representation of 
radiation protocols tested in vivo. Blue line represents protocol A; Light green line 
represents protocol B; and black line represents protocol C. D. Bioluminescence 
representative images of control and animals for the three different groups treated 
with radiation (Red: non-irradiated group; blue: protocol A; light green: protocol 
B; black: protocol C) at the humane endpoint. E. Survival curves comparing all 
groups analysed using Log-rank Mantel-Cox test (P= 0.4223). (Red, non-
irradiated: n= 24; blue, protocol A: n=20, P=0.1649; light green, protocol B: n=7, 




3.2. Mouse breast adenocarcinoma in an immunocompetent model 
(C57BL/6) 
To ensure that this phenotype is also replicated in an immunocompetent 
background and in an additional cancer type, we performed in vivo irradiation of 
E0771-BrM established brain metastases using protocol C (Smart et al., 2015). 
Given that our objective was to irradiate established metastases and that survival 
of mice inoculated with the syngeneic cell line is very close to the duration of the 
therapeutic intervention (Figure 1D and 3C), we incorporated a modification in 
the experimental design. We performed intracranial injection (2,5X104 cells), 
waited for 3 days, and started the protocol when the BLI signal in the brain 
reached 104 photon flux values (Figure 4A). This way we were able to mimic the 
clinical situation using an immunocompetent background. Similarly, to the 
immunosuppressed hosts, we found no differences in BLI signal between non-
irradiated and irradiated mice (Non-Irradiated: n=4; Irradiated: n=4; P=0.456) 
(Figure 4B and C). We additionally measured the mean area of the metastases 
using histology and confirmed that there was no difference between treatment 
groups (Non-Irradiated: n=4; Irradiated: n=4; P=0,350) (Figure 4D). Although the 
E0771-BrM model was engineered to express GFP, we have consistently 
observed that it tends to lose the expression of this reporter in vivo. These 
findings have been reported in other syngeneic and hypothesize to reflect the 
action of the immune system. However, this unexpected limitation did not involve 
a major impact in our main aims.   
In conclusion, in vivo irradiation following clinically relevant protocols applied to 
established brain metastases from lung or breast cancer in an immunocompetent 
or immunosuppressed host has no significant effect on local progression and, 




Figure 4. In vivo response to radiation in a syngeneic mouse model of brain 
metastasis.  
 
Figure 4. A. Schema of experimental design. B. Representative bioluminescence 
images in vivo and ex vivo at day 14 after intracranial injection. Representative 
images of brains from non-irradiated and irradiated mice, respectively, stained 
with DAPI. White lines surround the brain metastatic lesion. C. Quantification of 
ex vivo bioluminescence of non-irradiated and irradiated brains (Non-irradiated 
n=4; irradiated n=4; P= 0.456). D. Quantification of the mean area of brain 
metastasis lesions from non-irradiated and irradiated brains (Non-irradiated n=4, 
mean 11.35 ± 3.25; irradiated n=4, mean area= 8.97 ± 0.695; P= 0.350). 
3.3. Brain metastasis cells are radio-sensitive in vivo when growing 
extracranially 
In order to analyse whether resistance to radiation in vivo is dependent on the 
presence of BrM cells in the brain parenchyma and not acquired through a more 




subcutaneous space of the head and treated them with radiation (Figure 5A). 
1x105 cells H2030-BrM cells resuspended in Matrigel (1:2) were allowed to grow 
for 15 days to mimic the protocol applied to brain metastasis. At this moment, a 
mass could be detected in the head. The established tumour was irradiated with 
a single dose of 10Gy (Figure 5A). Given that the BLI was saturated in the control 
animals and thus not compatible to be used in the analysis, we performed 
histology. 72 hours after irradiation, a BrdU pulse  was administered (0,8mg/kg – 
100uL of a stock solution 0,2mg/mL) and 4 hours later mice were sacrificed. The 
proliferation index of the control and irradiated groups was determined (Figure 
5B). A significant decrease in BrdU was detected in irradiated tumours (p-
value=0,0071) (Figure 5C).  
Our experiment suggests that resistance of BrM cells to radiation therapy might 
be specifically induced in the brain parenchyma. This finding might involve that 
this form of resistance can be modulated and thus its molecular regulation could 
be used to generate better ways to apply this therapy.  
Figure 5. Subcutaneous H2030-BrM tumours are sensitive to radiotherapy.   
 
Figure 5. A. Schema of experimental design. Tumours were irradiated 15 days 
after a subcutaneous inoculation (SC: subcutaneous). B. Representative images 




BrdU to identify proliferating cells after irradiation. C. Quantification of BrdU+ cells 
per GFP area (Non-irradiated: n=4; irradiated: n=4; P= 0.0071).   
4. Resistance to radiotherapy can be modulated. 
The previous data suggest that BrM cells have different sensitivity to radiation 
when evaluated in vitro versus in vivo. To test this hypothesis, we reasoned that 
there should be conditions present in the in vivo environment that might induce 
the resistance. Metastatic cells must have the ability to re-initiate the tumour in 
secondary organs. This ability has been linked to stem cell-like properties (Celià-
Terrassa and Kang, 2016; Lambert, Pattabiraman and Weinberg, 2017). Cancer 
stem cells have been previously shown to correlate with increased resistance to 
therapy, including radiotherapy (Rycaj and Tang, 2014; Krause et al., 2017). In 
addition, another attribute of metastatic cells includes their ability to interact with 
the microenvironment, which has been also proved to mediate therapeutic 
resistance in a variety of different pre-clinical models (Sun et al., 2012; Qu et al., 
2019). Consequently, we designed in vitro experiments to mimic stem cell-like 
properties and the crosstalk with the microenvironment in order to evaluate their 
potential impact on increasing radiation resistance.  
4.1. In vitro conditions that increase radiation resistance. 
4.1.1. Tumour spheres are resistant to radiotherapy.  
First, to test the impact of stem cell-like properties on radioresistance, H2030-
BrM cells were grown under low attachment conditions to induce the generation 
of oncospheres. Oncospheres have been shown to enrich cancer cells with 
superior tumour initiating abilities that are more effective in generating 
metastases.  
BrM were cells were cultured for seven days under low attachment conditions. 
On day 7, oncospheres were irradiated (single dose of 10Gy) and then incubated 
for 72 hours, mimicking our previous in vitro assays. Subsequently, we analysed 
the effect of radiation by measuring the number and size of the spheres (Figure 




tested, which represent different tumour types and mouse/ human origins 
(H2030-BrM, P=0,504; E0771-BrM, P=0,7376; 482N1 P=0,668). 
These results suggest that oncospheres can be considered an in vitro surrogate 
with a superior resistance to radiation. 
Figure 6. Oncospheres are resistant to radiotherapy.  
 
Figure 6. A. Schema of experimental design. B, D and F. Representative images 
of H2030-BrM (B), E0771-BrM (D) and 482N1 oncospheres (F). In each image 
set, the upper image represents the control group and the lower image represents 
oncospheres irradiated with a single dose of 10Gy. C, E and G. Quantification of 
the area of spheres (x103 µm2) in the non-irradiated and irradiated groups of 





4.1.2. Co-culture of glial cells increases resistance of brain 
metastasis cells to radiation 
One of the most abundant components of the brain metastasis microenvironment 
are glial cells, including astrocytes as well as microglia (Quail and Joyce, 2017). 
Given the known influence of these cellular components on therapeutic 
resistance (Chen et al., 2016), we tested whether they could also influence the 
sensitivity of BrM cells to radiation. 
Glial cells were obtained from P0-P3 embryos, which is a commonly used 
protocol to isolate these cells for primary cultures (Schildge et al., 2013). BrM and 
glial cells were co-cultured under two conditions:  without direct cell-cell contact, 
using an insert chamber; or with direct cell-cell contact, by plating cancer cells 
and glial cells together. The proportion of cancer cells (H2030-BrM and MDA231-
BrM) (1,5x104) to glial cells (4,5x104) was prepared at 1:4. By performing these 
two approaches we were able to analyse the influence of the glial cell secretome 
(paracrine interactions) versus direct cell-to-cell interactions in radiation 
resistance.  
Interestingly, although exposure to the secretome of glial cells alone was not 
sufficient to change the sensitivity of BrM cells to radiation, as measured by the 
proportion of GFP+ cells remaining after treatment (Figure 7B), resistance to 
radiation was partially reduced when cancer cells were co-cultured with glial cells 
in the same well (Figure 7D). These results were reproduced in two different BrM 
cell lines from different primary tumours (H2030-BrM and MDA231-BrM).  
Consequently, cell-cell interactions with glial cells seems to correlate with an 




Figure 7. Co-culture of brain metastatic cells with glial cells increases resistance 
to radiation.  
 
Figure 7. A, C. Schema of experimental design including co-cultures with insert 
chamber (A) and with cell-to-cell interactions (C). B. Quantification of the 
percentage of brain metastatic cells (H2030-BrM and MDA231-BrM) alive 72h 
after irradiation, in non-irradiated (red), irradiated cells in adherent conditions 
(gray) and irradiated cells cultured with the insert containing the glia (green) 
(H2030-BrM irradiated not co-cocultured: 29.85% ±3.47 , irradiated co-cultured: 
33.4% ±8.50, P=0.611; MDA231-BrM irradiated not co-cocultured: 13.39% ±1.43, 
irradiated co-cultured: 15.55% ±2.15, P=0.475). D. Quantification of the 
percentage of brain metastatic cells (H2030-BrM and MDA231-BrM) alive 72h 
after irradiation, in non-irradiated (red), irradiated cells in adherent conditions 




irradiated not co-cocultured: 19%± 2.57, irradiated co-cultured:43,5% ± 7.76, 
P=0.0085; MDA231-BrM irradiated not co-cocultured: 15%± 1.77, irradiated co-
cultured:40,5% ± 5.12, P=0.0015). 
4.2. Ex vivo 
4.2.1. Rationale to use organotypic brain cultures 
We next looked for more sophisticated models that recapitulate both tumour 
initiation and interactions with the microenvironment. Brain organotypic cultures 
satisfy both demands when combined with BrM cells. This preparation has been 
extensively used to study the molecular mechanisms underlying metastatic 
colonization including the initiation of metastasis as well as the crosstalk between 
cancer cells and the microenvironment. Consequently, brain organotypic cultures 
are considered as an excellent surrogate to functionally validate brain metastasis 
mediators before testing them in vivo. Importantly, the flexibility of this assay 
allows mimicking both early and late stages of colonization.  
4.2.2. Brain organotypic cultures recapitulate in vivo resistance to 
radiation 
In order to generate brain organotypic cultures brains from healthy mice were 
sectioned to generate thick brain slices (250 µm) using a vibratome. Brain slices 
were then placed on top of a membrane floating on the culture media (see 
Methods). Each brain slice received 3x104 BrM cells, that were plated on the 
surface of the brain cultures, which is known to mimic the early stages of 
colonization. After overnight incubation, BLI emitted by BrM cells was acquired 
(day 0) and then brain slices were divided into 2 groups, non-irradiated and 
irradiated. The irradiated group received 10Gy in a single dose. 3 days after 
radiation, BLI was obtained again. The ratio between the BLI obtained at day 3 
versus day 0 for each individual slice indicates the growth rate of BrM cells after 
being irradiated.  
Our data show that, using this ex vivo model, a single dose of radiation of 10Gy 
is not able to compromise the growth rate of either H2030-BrM human lung 




P= 0.2385) or the E0771-BrM mouse breast cancer cells (Non-Irradiated: n= 8; 
Irradiated: n= 8 brain slices per condition, P= 0.2303). This is in sharp contrast to 
the radiation sensitivity observed for these cell lines in vitro (Figure 2C) and 
suggest that the induction of radiation resistance is highly dependent on the brain 
microenvironment. 
Plating cancer cells on top of brain slices is a useful surrogate for the initial 
phases of brain metastasis but does not allow to interrogate very closely the 
clinical situation in which radiation is typically applied on well-established brain 
metastasis. Therefore, we decided to repeat this experiment but considering 
established brain metastases. Organotypic cultures were generated from brains 
containing established brain metastases generated after 5 weeks from 
intracardiac injection of H2030-BrM cells. Established brain metastases were 
confirmed as previously described (see material and methods) using BLI values 
in vivo and ex vivo. Brains with confirmed established metastases were sectioned 
and those slices with BLI values between 5x104 to 1x106 photon flux were 
selected at day 0 for the experiment. Brain slices were then divided into irradiated 
(10Gy, single dose) and non-irradiated (control) groups and cultured for 3 days. 
At day 3 after irradiation, BLI images were taken and the growth rate of 
metastases was estimated by calculating the fold-increase compared to baseline 
values at day 0.  
As in the experiments scoring the early stages, radiation did not impair the growth 
of established metastases from H2030-BrM (Non-Irradiated: n= 10; Irradiated: n= 
10 brain slices per condition, P= 0.7111). 
In summary, organotypic cultures containing brain metastases reproduce the 
resistance to radiation observed in vivo, suggesting that this model could help to 




Figure 8. Organotypic cultures recapitulate resistance to radiation. 
 
Figure 8. A. and F. Schema of the experimental design including plating BrM cells 
on the brain slices (A), which mimics initial stages, as well as cultures obtained 
from mice with established brain metastasis (F). B, D and G. Representative 
images of cultured brain slices for 3 days. BLI is shown in non-irradiated brain 




results after plating BrM cells while G correspond to established metastases. C, 
E and H. Quantification of normalized photon flux in organotypic cultures of initial 
stages organotypic cultures of H2030-BrM (C) (Non-irradiated n= 23, 27.38± 
15.06; Irradiated n= 24, 8.95± 4.45; P= 0.2385) and E0771BrM (E) (Non-
irradiated n= 8, 11.88± 2.69; Irradiated n= 8, 7.49± 2.24; P=0.2303). 
Quantification of establish brain slices of H2030-BrM model (H) (Non-irradiated 
n=10, 2.52± 0.62; Irradiated n=10, 2.16± 0.74; P=0.7111) I. Representative 
images of immunofluorescence of non-irradiated and irradiated organotypic 
cultures with H2030-BrM cells. GFP: green fluorescence protein (green). BrdU: 
bromodeoxyuridine (red). ColIV: collagen IV (blue).  
5. Induced resistance to radiation is transient. 
In order to determine if the radiation resistance observed in oncospheres and glial 
co-cultures is permanently fixed in BrM cells or, on the contrary requires from 
constant induction, we performed re-irradiation experiments. BrM cells that were 
induced to be resistant to radiation after being cultured in oncospheres or with 
glial cells were re-plated in regular adherent culture conditions and interrogated 
for their ability to still resist radiation (see Figure 9A and 9C). Oncospheres were 
disaggregated and plated under adherent conditions and BrM cells were sorted 
from the glial cell culture and cultured under adherent conditions. A new dose of 
radiation (10Gy in a single dose) was given to these cells and 72 hours later we 
analysed the percentage of DAPI positive cells in both groups (Figure 9B and 
9C). Given that the sensitivity to a single dose of radiation (10Gy) reduced cell 
viability (Figure 9B, D) to the levels detected in those BrM cells irradiated de novo 
(Figure 2C), we conclude that resistance is not permanently induced in BrM cells 
after special culture conditions. In order to be maintained, the resistance requires 
constant induction. 
We also proposed that these in vitro surrogates inducing resistance could be 
dissected at the molecular level to interrogate potential sources responsible to 




Figure 9. Radiation resistance is a transient phenotype.  
 
Figure 9. A and C. Schema of experimental design. B and D. Quantification of 
H2030-BrM 72 hours after being re-irradiated when compared with the control 
group (non-irradiated). Nor H2030-BrM obtained from oncospheres (B) neither 
from co-cultures were able to show any resistance (B and D, 5 fields of view were 
quantified from 5 images per coverslip from 3 different coverslips per condition 
(B, n= 15, 41.28± 6.07, P=0.0436; D, n= 5, 26.32± 3.54, P= 9.89x10-7).   
6. Resistance to radiation correlates with more efficient DNA damage 
repair 
To obtain molecular evidences of the radiation resistance phenotype, we 
analysed the level of -H2AX, a classical marker of DNA damage (Sak and 
Stuschke, 2010), in BrM cells after irradiation. Radiation causes DNA damage 
that activate DNA repair mechanisms. -H2AX is one of the pioneer sensors of 
DNA damage and accumulate in these lesions forming foci that could be 
visualized by immunofluorescence. Sustained levels of -H2AX is indicative of 
persistent damage that is not repaired, which could lead to apoptosis (Rogakou 




BrM cells cultured under regular adherent conditions that received radiation 
(single dose of 10Gy), showed an increase of expression of -H2AX 1 hour after 
irradiation (Figure 10A). 24 hours after irradiation, we observed that BrM cells 
maintained high expression of -H2AX in their nuclei (Figure 10A). This finding, 
which might suggest the inability of BrM cells to resolve the radiation-induced 
DNA damage, could be the underlying cause leading to cell death detected after 
72h (Figure 2C). 
In contrast to this observation, when the same protocol of radiation was applied 
to the H2030-BrM cells grown under conditions correlating with radio-resistance 
(oncospheres, co-cultures, organotypic cultures and brain metastasis in vivo), the 
levels of -H2AX 24 hours after irradiation were drastically reduced (Figure 
10B,C,D). In all the conditions we analysed 5 fields of view from 3 slices of 3 
different wells of cells (A) or oncosphere cultures (B), six different brains were 
used to obtain ex vivo (C) and in vivo samples (D), three for each experiment. 
In conclusion, we propose that one of the underlying mechanisms of resistance 
that could explain the lack of sensitivity to radiotherapy might involve a superior 




Figure 10. Resistance to radiation correlates with less persistent DNA damage. 
 
Figure10. Representative images of H2030-BrM cells stained with -H2AX 
antibody to score persistence of DNA damage over time. A. Adherent H2030-BrM 
cells maintain a high expression of -H2AX 24h after irradiation. B, C and D. 
H2030-BrM grown as oncospheres (B), on organotypic cultures ex vivo (C) or in 
vivo as brain metastases (D) efficiently reduced -H2AX levels 24 hours after 
irradiation.  
7. Molecular dissection of radiation resistance 
Given that our main goal was to improve the efficacy of radiotherapy, we 




regulated genes that could be responsible for the phenotypes observed. In this 
sense we argue that different culture conditions correlating with radiation 
resistance might share commonly deregulated genes that might be responsible 
for the resistance phenotype. We hypothesize that it is the culture condition itself 
rather than the radiotherapy per se the inducer of potential transcriptomic 
changes. Thus, we focused on deregulated genes independently of the 
application of radiation, although their expression should not be influenced in an 
opposite way by this treatment. 
In order to avoid any influence of radiation in cell death, we collected our samples 
24 hours after applying radiation, since at this stage no changes in this sense 
were detected (data not shown). We focus our transcriptomic analysis on the 
H2030-BrM cell line, but we expanded the validation to other models. Three 
independent replicas were generated in each in vitro culture condition, including 
oncospheres and co-cultures with cell-cell-interactions. In the case of co-cultures, 
we isolated cancer cells by sorting based on GFP expression 24h after radiation 
and extracted RNA from those cells. All samples were tested for integrity using 
the bioanalyzer and submitted for RNA sequencing. The library generated by 
RNA sequencing was analysed to compare radiosensitive and radioresistant 
conditions. 
7.1. Transcriptomic profile of radiation resistance in BrM cells 
We focused our analyses on deregulated genes that were equally present in the 
two resistant surrogates, oncospheres and co-cultures with glial cells. Although 
the two resistant conditions are very different, we reasoned that if there was a 
key mechanism to resist radiation, it would be enriched in both conditions 
independently of the upstream stimuli that activated it, which is expected to be 
specific to each surrogate. Under these criteria, only ten genes were identified as 
deregulated across groups. Of these, two genes were up-regulated (S100A9, 
CITED4) and 8 genes were down-regulated (ADM2, SLC1A4, B7H6, ASNS, 
PPP1R15A, FAT4, SESN2, MAP1B). The 10 gene signature was also present in 
the non-irradiated resistant surrogates, which suggest that its acquisition is not 




Figure 11.Transcriptomic profile of in vitro resistant surrogates. 
 
Figure 11. A and E. Schema of experimental design represents the conditions 
tested by GSEA analysis, including in vitro surrogates’ analysis (A) and the 
analysis comparing adherent cells vs co-opting cells transcriptome (E). B. and C. 
Representation in a Venn diagram of the up regulated genes (B) and the down 
regulated genes (C) across the resistant groups. D. Heatmap representing gene 
expression of the 10 genes identified as deregulated across resistant groups. (up 
regulated – S100A9, CITED4; down regulated - ADM2, SLC1A4, B7H6, ASNS, 
PPP1R15A, FAT4, SESN2, MAP1B) at the comparation of sensitive (adherent 
cells and insert co-cultures) vs resistant surrogates (oncospheres and cell-cell 




genes of interest when we compared cells in adherent condition vs co-option 
cells. G. Gene ontology analysis graph of RAGE receptor H. Gene set enrichment 
representative graphs of the pathways found to be enriched. 
Given that cancer cells growing in organotypic brain cultures also become highly 
resistant to radiation, we made use of the data generated in our previous 
publication (Valiente et al., 2014) profiling H2030-BrM growing in brain slices in 
comparison to the same cell line under regular adherent culture conditions. 
Interestingly, in this very different experimental condition, the same 10 gene 
signature was also present (Figure 11). 
Out of the 10 gene signature of radiation resistance, we decided to further assess 
S100A9 because it was the highest up-regulated gene in each of the three 
resistance surrogates (oncospheres, co-cultures and organotypic cultures). 
S100A9 is a calcium binding protein that has been reported to be involved in 
inflammatory processes and cancer progression (Gebhardt et al., 2006). This 
protein can be found in the cytoplasm of myeloid cells and cancers cells but it can 
also be secreted, usually under circumstances involving stress (Tardif et al., 
2015; Jonasson et al., 2017). Secreted S100A9 binds RAGE and TLR receptors 
that activate various downstream signalling pathways, including the NFκβ 
pathway (Riva et al., 2012), a pathway that has been linked to radiation resistance 
in brain tumours (Bhat et al., 2013). 
Gene Set Enrichment Analysis (GSEA) showed significant enrichment of 
pathways related to NFκβ activation including MYD88 cascade; TRAF6 induction 
of NFκβ and MAPK; and MAPK activation in TLR cascade (Figure 11H). This 
finding applied to all in vitro and ex vivo conditions, which reinforces the potential 
involvement of this pathway in the resistance to radiation of brain metastasis 
surrogates. In addition to the identification of potential pathways activated by 
S100A9, we also found the enrichment of one of its receptors, RAGE, using the 




8. Identification of S100A9-RAGE-NFKB axis as a potential inducer of 
radiation resistance 
8.1. Validation of S100A9 enrichment in brain metastasis and 
development of a loss of function strategy.  
Given the increased expression of S100A9 at the transcriptional level in all 
resistant surrogates, we hypothesized that it could be an important mediator of 
radiation resistance in vivo. First, we validated by qRT-PCR the increased 
expression of S100A9 in oncospheres compared to adherent cells independently 
of irradiation (0Gy, P=0,0148; 10Gy, P=0,00157) (Figure 12A). In addition, we 
analysed S100A9 expression levels in situ by using S100A9 specific primers to 
human gene in brains containing human metastatic cells from H2030-BrM and 
brains with metastatic lesion of MDA231-BrM cells (figure 12 B). In these two 
models increased expression levels were evident when comparing cells growing 
under adherent conditions in vitro and cells growing inside the mouse brain 
(P=0,0108; P=0,0003, respectively). Besides that, we expanded the analysis to 
the protein levels of S100A9 and we included an additional model, including the 




 Figure 12. Validation of S100A9 enrichment in brain metastasis 
 
Figure 12. A. Quantification of S100A9 mRNA levels in oncospheres compared 
to adherent cells in irradiated and non-irradiated conditions. B. Quantification of 
S100A9 mRNA levels in adherent cells compared to BrM cells growing on a 
mouse brain (in-situ) in non-irradiated samples of H2030-BrM (left) and MDA231-
BrM (right). C. Representative images of S100A9 protein expression levels 
(brown and red colour) on BrM cells (green). samples brains from mice with brain 
metastatic lesions from three different BrM cell lines (H2030-BrM on the left, 
MDA231-BrM on the middle and E0771-BrM on the right picture).  
In order to functionally address whether the increased levels of S100A9 are 
responsible for mediating radiation resistance, we performed a knockdown in two 
different BrM models. 5 different shRNAs lentiviral vectors (pLKO.1 vectors) 
against the human S100A9 gene and 5 different shRNAs lentiviral vectors against 
the mouse s100a9 gene were used in the H2030-BrM and the E0771-BrM cell 
lines, respectively. Two shRNA that yielded more than 80% reduction in gene 




validation ex vivo and in vivo. None of the cell lines showed any defect in vitro 
under normal adherent culture conditions (data not shown). 
 Figure 13. S100A9 knockdown selection for human and mouse BrM cell. 
 
Figure 13. A. Quantification of S100A9 mRNA levels in H2030-BrM control cells 
compared to H2030-BrM cells engineered with two different knockdowns 
(ShS100A9#1 and ShS100A9#2). B. Quantification of S100A9 mRNA levels in 
H2030-BrM control cells compared to E0711-BrM cells engineered with two 
different knockdowns (Shs100a9#1 and Shs100a9#2) 
8.2. Ex vivo evidence of the role of S100A9 as a mediator of radiation 
therapy. 
In order to evaluate the potential role of S100A9 in mediating radiation resistance 
of brain metastatic (BrM) cell lines we use organotypic cultures.  BrM cells (3x104 
of cancer cells) engineered with control shRNA or shRNA targeting S1009 were 
plated on top of alive brain slices. Plated BrM cells and brain slices were 
incubated overnight and the bioluminescence derived from the cancer cells, 
engineered to express luciferase, was acquired 18 hours after plating (Day 0). 
Subsequently, organotypic cultures were divided into two groups, one that 
received a single dose of 10Gy of radiation and another that was not treated. 
Brain slices were incubated for 3 days, after which bioluminescence imaging (BLI) 




of BrM cells from each slice, we calculated the ratio of bioluminescence between 
day 3 and day 0 and termed this value as “fold increase”.  
Control H2030-BrM cells demonstrated resistance to radiation, as expected (see 
figure 2C). Strikingly, S100A9-knockdown cells, which do not show any growth 
rate disadvantage with respect to control cells in the non-irradiated group, 
showed  decreased bioluminescence levels in the irradiated group (Non-
irradiated: shControl, n =9; shS100A9#1, n= 6; shS100A9#2, n= 13 brain slices 
per group, P= 0.5231; Irradiated: shControl, n= 10; shS100A9#1, n= 4; 
shS100A9#2, n=10 brain slices per group, P= 0.005). 
Figure 14. Ex vivo evidence of the role of S100A9 as a mediator of radiation 
therapy 
 
Figure 14. A. Schema of experimental design. B. Representative images of 
cultured brain slices for 3 days. BLI is shown in H2030-BrM control cells (top 
images) and in stable knockdown H2030-BrM cells lacking expression of S100A9 
(bottom images), in non-irradiated brain slices (left images) and irradiated slices 




organotypic cultures of H2030-BrM cells (Control) and two different H2030-BrM 
knockdown cell lines (shS100A9#1 and #2). We compared the different groups 
(control vs knockdown) stratified by irradiation treatment. 
8.3. Targeting S100A9 in clinically relevant experimental models 
confirms its involvement in therapy resistance  
In the clinical setting, brain metastases are usually treated when they have 
already formed macrometastases, which does not correspond with our previous 
data generated by plating BrM cells in brain slices. Therefore, in order to validate 
our findings in clinically relevant models, we generated established brain 
metastases in mice, generated organotypic cultures and irradiated them ex vivo.  
First, we evaluated the ability of H2030-BrM shS100A9 cells to generate brain 
metastases. Intracardiac injection of shControl (n=10, nude Foxn1-/- mice) and 
shS100A9 (sh#1: n=5, nude Foxn1-/- mice; sh#2, n=5 nude Foxn1-/- mice, sh#2) 
H2030-BrM cells developed brain metastases with similar growth rates as 
measured by non-invasive BLI (add BLI values and P value) and showed similar  
metastatic load in the brain at the endpoint, as confirmed by ex vivo BLI. 
Brains with established metastases were processed at 5 weeks after intracardiac 
injection. Organotypic cultures with metastases were exposed to a single (10Gy) 
dose of radiation. Three days later, we pulsed the slices with BrdU for four hours 
and fixed them using paraformaldehyde. Immunofluorescence imaging of BrdU 
incorporation demonstrated that S100A9-knockdown H2030-BrM cells 




Figure 15.  S100A9 is responsible for resistance to radiation in established 
metastasis ex vivo  
 
Figure 15. A. Schema of the experimental design including cultures obtained from 
mice with established brain metastasis. B. Representative images of 
immunofluorescence of irradiated brain slices, three days after irradiation. 
Immunofluorescence images shown levels of expression of BrdU on H2030-BrM 
control cells (top image) and in stable knockdown H2030-BrM cells lacking 
expression of S100A9 (bottom image) both in establish brain slices. GFP: green 
fluorescence protein (green). BrdU: bromodeoxyuridine (red). C. Quantification 
of percentage of BrdU+ cells per GFP+ cells. (Control n=15 FOV; shS100A9#2 
n=15 FOV; P<0.001) 
We next performed an in vivo experiment to further test the potential role of 
S100A9 as a mediator of radiation resistance in brain metastasis. Three groups 
of mice were intracardiacally injected with three stably transfected cell lines 
derived from H2030-BrM:  shControl, shS100A9#1 or shS100A9#2.  
Brain metastases were established during the second week after the injection 
(Mean bioluminescence value  SEM: shControl n= 10, 1.39x104  1.41x103, 
shS100A9#1 n=10, 1.02x104  1.76x103 or shS100A9#2 n=10, 1.14x104  
1.50x103). We applied protocol C (Figure16 E) of whole brain radiotherapy 




a total dose of 30Gy per mouse. This is the most clinically relevant of the 
commonly used radiation protocols (see Methods). Mice were followed weekly 
with non-invasive BLI until week 5 after intracardiac injection. At this time-point 
the humane endpoint is reached, and mice were sacrificed.  
BLI in vivo showed a reduction in brain metastases burden in the groups injected 
with S100A9 knockdown cells. In fact, this finding was already evident when only 
half of the total radiation dose had been delivered (shControl: n=8, 
5.39E+05±1.06E+05; shS100A9#1: n=8, 4.45E+04±2.33E+04; P=0,001; 
shS100A9#2: n=8, 1.23E+05±3.83E+04; P=0,005) (Figure 15 F and G). Although 
brain metastases with S100A9 knockdown continue growing, the growth rate was 
highly reduced compared to non-irradiated mice (Figure 15). Ex vivo 
bioluminescence taken at the endpoint confirmed reduced brain metastatic 
burden in irradiated mice harbouring S100A9-knockdown as compared to 
irradiated mice harbouring control tumours (shS100A9#1: n=8; P=0,016; 
shS100A9#2: n=8 P=0,044). Similarly, analysis of the histology confirmed that 
reduced levels of S100A9 correlated with less GFP+ metastases (shS100A9#2; 
P<0,001). Of note, extracranial metastases (non-irradiated) grew similarly in both 
groups.  
These results unequivocally demonstrate that S100A9 mediates radiation 




Figure 16. S100A9 is responsible for resistance to radiation in established 
metastasis in vivo. 
 
Figure 16. A. Representative bioluminescence images in vivo and ex vivo, 5 
weeks after intracardiac injection. BLI is shown brain metastatic lesions in mice 
injected with H2030-BrM control cells (left image) and mice injected with a stable 
knockdown H2030-BrM cells lacking expression of S100A9 (right image), in non-
irradiated conditions. B. Quantification of ex vivo bioluminescence of control, 
shS100A9#1 and shS100A9#2 brains in non-irradiated conditions (Control n=10; 
shS100A9#1 n=5; shS100A9#2 n=5; P= ns.). C. Representative images of brains 




GFP reporter (green) and S100A9 protein (red). D. Quantification of the mean 
number of brain metastasis lesions from H2030-BrM control cells and stable 
knockdown H2030-BrM cells lacking expression of S100A9 in non-irradiated and 
irradiated brains (Non-irradiated: control n=2, mean 35± 8; shS100A9#2 n=2, 
mean 22.5 ± 5.5; irradiated: control n=5, mean 24.6± 1.66; shS100A9#2 n=5, 
mean 4.2 ± 1.77 ; P< 0.001). E. Representative bioluminescence images in vivo 
and ex vivo at 5 weeks after intracranial injection.  BLI images shown in vivo 
control (left image), shS100A9#1 (central image) and shS100A9#2 mice (left 
image) from mice treated with 30Gy of radiation (protocol C, described before), 
respectively. As well as shown ex vivo bioluminescent images of brains and 
extracranial metastasis from control, shS100A9 #1 and #2 mice. F. and G. 
Quantification of in vivo bioluminescence of irradiated brains from control (left 
image), shS100A9#1 (central image) and shS100A9#2 mice (left image), 
respectively. (Week1: control n=9, mean 1.39E+04 ± 1.41E+03;shS100A9#1 
n=8, mean  1.02E+04 ± 1.76E+03; shS100A9#2 n=8, mean  1.14E+04 ± 
1.50E+03; P=ns; Week3: control mean 5.39E+05± 1.06E+05; shS100A9#1, 
4.45E+04± 2.33E+04, P=0,001; shS100A9#2, mean 1.23E+05±3.83E+04; 
P=0,005; Week5: control, mean 1.05E+07± 3.28E+06; shS100A9#1, mean  
4.47E+05± 2.14E+05, P=0,016;  shS100A9#2, mean  2.10E+06± 9.48E+05, 
P=0,044) 
Given that limited response to WBRT has been observed not only in patients with 
lung cancer but also in breast cancer brain metastases we wanted to know 
whether S100A9 could be also important in other model established from a 
different cancer type. Our hypothesis however proposed that S100A9 might be 
induced by aspects inherent to the process of colonization of cancer cells within 
the brain tissue environment.  
Consequently, we performed an additional in vivo approach targeting s100a9 in 
a mouse BrM model of triple negative breast cancer that we established (Figure 
1). In addition to validate S100A9 in a different cancer type, this model also allows 
us to confirm our hypothesis in an immunocompetent host.  
As previously described (Figure 4), we performed these experiments by 




the ability of E0771-BrM cells to colonize the brain (data not shown). We 
sacrificed the animals at day 15 after intracranial injection and analyze the BLI. 
There were no differences in brain metastasis formation when we compared the 
irradiated control group with the knockdown (E0771-BrM control: n=10; E0771-
BrM shs100a9#43: n=10; E0771-BrM shs100a9#43: n=10; P= 0,4981).  
Subsequently, to test the role of S100A9 in radiation resistance on a syngeneic 
model, we inoculated a group of 10 mice per condition including shControl, 
shs100a9#43 and shs100A9#44 E0771-BrM cells. Three days after injection, 
once brain metastasis had been established (Mean bioluminescence value  
SEM: shControl= 2.68x104  9.23x103, shs100a9#43= 2.83x104  1.08x104 or 
shs100a9#44= 3.03x104  1.28x104), we started the radiation protocol. Mice 
received a fractionated dose of 3Gy per day for 10 days to reach a total radiation 
dose of 30Gy at the end of treatment. Metastasis growth in the brain was 
evaluated by BLI images every 3 days. Fourteen days after intracranial injection, 
the animals were sacrificed, and the brains were analysed by BLI ex vivo. 
We observed a clear trend of lower bioluminescence in the brains s100a9 
knockdowns when compared with the control group (E0771-BrM shControl: n=10; 
E0771-BrM shs100a9#43: n=8; P= 0.0606; E0771-BrM shs100a9#44: n=7; P= 
0,1225). 
Although we require to increase the number of mice, these results suggest that 




Figure 17. Validation of S100A9 as a mediator of radiation resistance in a 
syngeneic model of brain metastasis. 
 
Figure 17. A. Representative bioluminescence images in vivo and ex vivo at day 
14 after intracranial injection. Representative images of brains from non-
irradiated and irradiated mice, respectively, stained with DAPI. White lines 
surround the brain metastatic lesion. B. Quantification of ex vivo bioluminescence 
of non-irradiated and irradiated brains (Non-irradiated n=4; irradiated n=4; P= 
0.456). C. Quantification of the mean area of brain metastasis lesions from non-
irradiated and irradiated brains (Non-irradiated n=4, mean 11.35 ± 3.25; irradiated 
n=4, mean area= 8.97 ± 0.695; P= 0.350). D. Representative BLI images of brains 
from shControl (top image) and shs100a9 #43 and #44 mice (bottom) at day 15 
after intracranial injection. E.  (E0771-BrM shControl: n=10; E0771-BrM 




9. Targeting S100A9-dependent signalling pathway to sensitize brain 
metastases against radiotherapy. 
9.1. RAGE but not TLR2 levels are increased upon radiation.  
In order to elucidate the autocrine pathway responsible for S100A9-dependent 
radiation resistance phenotype that we have observed, we evaluated the 
expression of the different receptors of S100A9, including the receptor for 
advanced glycation end products (RAGE) and Toll-like receptors 2 (TLR2). We 
analysed their levels in different assays. Under non-irradiated conditions, we 
observed that there was no significant difference in the expression of neither 
RAGE nor TLR2 neither in H2030-BrM cells growing under adherent conditions 
or H2030-BrM cells that growing inside the brain tissue (RAGE n=3, P=0,2098; 
TLR2 n=3, P= 0.3564). 
In contrast, after irradiation we observed a significant increase in the expression 
of RAGE in H2030-BrM either under normal adherent conditions or when cells 
were cultured as oncospheres (Figure 17B). In contrast, this trend did not affect 
TLR2, suggesting that cancer cells might become sensitized to extracellular 
S100A9 levels after receiving radiation by increasing RAGE, which might act as 
a mechanism to further promote the acquired resistance (Figure 17A). 
Figure 18. RAGE but not TLR2 levels are increased upon radiation 
Figure 18. A. Schematic model of the pathway S100A9-TLR2/RAGE-NFκβ. B. 




expression comparing H2030-BrM adherent cells with H2030-BrM oncospheres 
on irradiated condition.   
9.2. NFκβ pathway is induced upon radiation 
To evaluate the downstream effects of S100A9-dependent pathways in BrM cells, 
we engineered H2030-BrM cells with a NFκβ pathway reporter (REF). Our 
previous data suggest that BrM cells cultured in particular conditions (i.e. 
oncospheres, organotypic cultures) increase the production of S100A9 but it is 
not until they receive radiation that they are sensitized due to the increase in the 
RAGE receptor. Consequently, H2030-BrM cells engineered with the NFκβ-
mCherry reporter showed increased red fluorescence when plated in brain slices 
that were treated with radiation (single dose, 10Gy) (Figure 18) (Control n=11; 
Irradiated n=7; P= 0.0268).  
Figure 19. NFκβ pathway is induced upon radiation 
Figure 19. A. Representative images of immunofluorescence of H2030-BrM cells 
plaited on brain slices. Immunofluorescence images shown levels of expression 
of mCherry on H2030-BrM Non-irradiated (left image) and irradiated (right 
image). GFP: green fluorescence protein (green). mCherry (red). B. 
Quantification of percentage of number of mCherry positive cells per number of 




9.3. Pharmacologic blockade of S100A9 pathway increases sensitivity to 
radiation  
In order to functionally validate S100A9-RAGE and its downstream signalling 
activating NFκβ as part of radiation resistance, we tested two different 
pharmacological inhibitors. FPS-ZM1 is a BBB-permeable RAGE receptor 
inhibitor which has been shown to be safe in the clinical setting (Sun et al., 2012; 
Qu et al., 2019). Bay-117082 is an IKK inhibitor which favours NFκβ sequestration 
and loss of its transcriptional activity (Pierce et al., 1997; Kamthong and Wu, 
2001). Given that RAGE is a known activator of NFκβ, we reasoned that inhibiting 
this pathway should mimic direct RAGE inhibition.  
We tested these two inhibitors in organotypic brain cultures treated with radiation 
to evaluate whether resistance could be impaired (Figure 19A). BrM cells (H2030-
BrM) were plated on top of normal brain slices and either FPS-ZM1 (10uM), Bay-
117082 (50uM), or vehicle (DMSO) were added to the culture media. 18 hours 
after plating BrM cells, a single dose of radiation (10Gy) was applied to a group 
of experimental samples. BLI was acquired 72 hours post-irradiation and BrdU 
was added to the media 4 hours before fixation. Both bioluminescence (Figure 
19B and E) and BrdU staining (Figure 19D and G) demonstrated decreased 
values when RAGE and Iκκ inhibitors were used combined with radiation (Figure 
19C and F) (Non-irradiated + FPS-ZM1, n=14; Irradiated + FPS-ZM1, n=14; BLI 
values P= 0,027; BrdU+ cells P=0,035; Non-Irradiated + Bay11-7082, n= 12; 
Irradiated + Bay11-7082, n=12; BLI values P=0,04; BrdU+ cells P=0,014). 
These results suggest that targeting S100A9 receptor RAGE and the 





Figure 20. Pharmacologic blockade of S100A9-RAGE-NFκβ pathway. 
 
Figure 20 A. Schema of the experimental design including plating BrM cells on 
the brain slices (left schema), which mimics initial stages, treated with the inhibitor 
added to the culture media. A schematic model of the S100A9-RAGE-NFκβ 
pathway and the targets of the inhibitors (right scheme). B and E. Representative 
images of cultured brain slices for 3 days. BLI is shown in non-irradiated brain 
slices (top image) and irradiated slices (bottom image). B correspond to results 
after treatment with FPS-ZM1 while E correspond to brain slices treated with Bay 
11-7082. C and F. Quantification of normalized photon flux in organotypic cultures 
comparing the conditions Non-irradiated plus inhibitor vs Irradiated plus inhibitor, 




ZM1 n=13, 11.20± 3.00; irradiated plus FPS-ZM1 n=12, 3.57 ± 3.06; P= 0.027; 
Non-irradiated plus Bay 11-7082 n=12, 5.17± 0.82; irradiated plus Bay 11-7082 
n=12, 2.90± 0.68; P= 0.045). D. and G. Representative images of 
immunofluorescence of non-irradiated and irradiated organotypic cultures with 
H2030-BrM cells treated with FPS-ZM1 (D) or with Bay 11-7082 (G). GFP: green 
fluorescence protein (green). BrdU: bromodeoxyuridine (red). White arrows point 
the positive BrdU cells.  
10. S100A9 in human brain metastasis  
In order to confirm our findings in human samples we stained S100A9 in 26 brain 
metastasis samples from patients with lung cancer (8 samples, 30.77%) and 
breast cancer (18 samples, 69.23%). The expression level of S100A9 was scored 
from 0 (no S100A9 signal) to 3 (highest level) by an expert pathologist. We found 
that only 15% of the cases (4/26) were completely negative for S100A9 all the 
other samples were positive to S100A9 (22/26), suggesting that our findings 
might well be conserved in human, since most patients do not respond to 
radiotherapy.  
10.1. Targeting S100A9-dependent pathway in human brain 
metastasis 
In order to functionally validate the S100A9-RAGE-NFκβ pathway in human brain 
metastases, we performed patient-derived organotypic cultures (PDoC) from 
fresh neurosurgeries obtained through a collaboration with Hospital 12 de 
Octubre. Two lung adenocarcinoma brain metastases (Sample#1 and sample#2) 
were sectioned with the vibratome alive. Sections were plated on membranes 
and cultured for 3 days after receiving a single dose of radiation (10 Gy). BrdU 
was administered 4 hours before fixation. Sample#1 was scored as 0, meaning 
absence of S100A9, while sample#2 had a score of 1, indicating the presence of 
S100A9. Interestingly, while sample#1 showed a significant reduction of BrdU 
incorporation upon radiation treatment, sample#2 was not affected (Figure 20C) 
(non-irradiated without inhibitor treatment: n=11; irradiated without inhibitor 
treatment: n=9; P=0.0155), suggesting that resistance to radiation might correlate 




Given our previous data regarding the ability of FPS-ZM1 to radiosensitize 
S100A9-expressing brain metastatic cells, we applied the same strategy to 
sample#2 and observed that inhibition of RAGE blocked resistance to radiation 
(Figure 20C) (non-irradiated without inhibitor treatment: n=8; irradiated without 
inhibitor treatment: n=8; P=0.1440; non-irradiated plus inhibitor: n=8; P=0.6304; 
irradiated plus inhibitor n=9; P=0.0069), 
Consequently, in agreement with our experimental models, the presence of 
S100A9 in PDoC correlates with resistance to radiation, which could be 
ameliorated by using the BBB-permeable RAGE inhibitor FPS-ZM1. Although 
these results are encouraging, additional samples are needed in order to provide 
more solid evidence in human tissue.  





Figure 21. A. Schema of the experimental design of patient derived organotypic 
cultures (PDoC). B. Representative images of immunofluorescence of four 
different samples of brain metastasis tissue from four different patients. Dapi: 
staining the cell nuclei (blue). S100A9 protein expression (red). C. Quantification 
of mean of BrdU per field of view in organotypic cultures comparing four groups 
of conditions: non-irradiated without inhibitor treatment (red), irradiated without 
inhibitor treatment (blue), non-irradiated plus inhibitor (orange), irradiated plus 
inhibitor (green). On the left we can see graph of sample with S100A9 expression 
negative (score 0, left graph) (Mean BrdU positive cells/FOV ± SEM: non-
irradiated without inhibitor treatment: n=11, 166± 20.63; irradiated without 
inhibitor treatment: n=9, 47.8± 9.65; P=0.0155; non-irradiated plus inhibitor: 
n=10, 99± 11.54; P=0.0216; irradiated plus inhibitor n=9, 82.25± 13.58), on the 
right graph we analysed the results of sample with S100A9 low expression 
(score1) (Mean BrdU positive cells/FOV ± SEM: non-irradiated without inhibitor 
treatment: n=8, 155.37± 21.81; irradiated without inhibitor treatment: n=8, 
116.38± 8.94; P=0.1440; non-irradiated plus inhibitor: n=8, 172.88± 25.14; 














































In the work described here, I have generated a novel, syngeneic, 
immunocompetent model of breast cancer brain metastasis (E0771-BrM). This 
model is suitable for in vivo, ex vivo, and in vitro modelling of brain metastasis. 
Due to a limited number of experimental models that allow studying brain 
metastasis in an immunocompetent background and the importance of the 
immune system in cancer including brain tumours, we are confident that this new 
model will be well-received by other researchers of the field. In fact, we have 
already distributed this cell line with various national and international 
laboratories interested in brain metastasis, evidencing the importance of this new 
model for the field. 
With respect to the central question of my thesis, we have demonstrated that 
despite ubiquitous in vitro radiation sensitivity, BrM models are largely radiation-
resistant in vivo. Although the result was unexpected regarding the sharp contrast 
in the phenotype between these experimental conditions, several clinical 
observations have claimed that the benefits of whole brain radiation therapy 
(WBRT) is limited and consequently, the overall survival of patients does not 
increase after treatment (Kocher et al., 2011). In conclusion, in vivo irradiation of 
established metastases from lung or breast cancer, using a protocol similar to the 
current standard of care, has no significant effect on metastatic progression or 
survival in vivo in experimental BrM models. This finding seems independent of 
the primary source or the metastasis as well as of the acquired immune system. 
We were able to recapitulate the radiation resistance observed in vivo using ex 
vivo organotypic brain cultures, co-cultures with glial cells or simply by growing 
cancer cells as oncospheres. With these different culture techniques, we have 
been able to interrogate in an unbiased way potential mediators involved in 
radiation resistance in brain metastasis. Given the transient character of the 
resistance that we have found, we propose that it has a strong dependence on 
the context and thus might be highly influenced by the microenvironment. In 
addition, we have demonstrated that in vitro/ ex vivo approaches are useful to 




observe that the levels of DNA damage induced by gamma irradiation in cancer 
cells cultures in vitro and ex vivo under resistance conditions were recovered as 
fast as in vivo, which confirms the existance of a molecular rationale behind the 
resistance phenotype. We hypothesize that these findings suggest an enhanced 
ability to repair DNA under these experimental conditions.  
However, none of our experimental designs nor the data we have generated were 
detailed enough for claiming any stronger than this about the molecular 
mechanisms that could be responsible for this phenotype.  Future studies should 
clarify the molecular mediators of the increased efficiency of DNA repair in brain 
metastasis.  
Our main contribution to the mechanism behind radiation resistance in brain 
metastasis was the identification of a ten-gene signature. Within this signature 
we identified S100A9, an inducer of the NFκβ pathway, as a target of particular 
interest since it was represented in all resistance surrogates.  Given that the 
implication of NFκβ in radiation resistance is well documented and includes 
primary brain tumours (Bhat et al., 2013) we became interested to functionally 
validate this finding.  
We provided the evidence that S100A9 is indeed mediating radiation resistance 
of brain metastasis in vivo in two models of brain metastasis and validated this 
finding in human samples. 
In view of our findings, we propose a model depicted in Figure 22. In brief, the 
levels of inflammatory cytokines such as TNFα would dramatically increase within 
the brain microenvironment following the colonization by cancer cells (Seike et 
al., 2011; Xing et al., 2015). High levels of TNFα activate TNFα receptor 1 (we 
found in this work the expression of this receptor in our BrM cells, data not shown) 
present in brain metastatic cancer cells as well as in other cells of the 
microenvironment. It is known that activation of the TNFR1 leads to the induction 
of S100A9 expression (Bianchi, Giambanco and Donato, 2010).  S100A9 is 
strongly induced in metastases. Once the cancer cells are irradiated, RAGE 
receptor expression increases. Thus, after irradiating cancer cells in the brain 
there is an increase in both the ligand (S100A9) and the receptor (RAGE). 




RAGE-NFκβ pathway. The NFκβ pathway might further increase the expression 
of S100A9 through a positive feedback loop but also drive the expression of other 
molecules known to be protective against radiation, such as CEBPB (Du et al., 
2019).  As a result of this process, brain metastatic cancer cells would become 
resistant to radiation.  
Looking for options to translate our findings into better opportunities for cancer 
patients we identified a potential radiosensitizer. FPS-ZM1, a BBB-permeable 
RAGE antagonist (H. Wang et al., 2018) that has been used in experimental 
treatments for Alzheimer (Deane et al., 2012; Walker et al., 2015), was able to 
increase the sensitivity to radiation in brain metastatic cancer cells. Due to our 
positive results with this inhibitor ex vivo in mice and human patients brain 
metastases we speculate that the use of FPS-ZM1 as a radiosensitizer could be 
useful for patients with radiation-resistant brain metastasis, thus high for S100A9 
levels. However, the in vivo validation using experimental brain metastasis 
models remains to be tested.   
Besides the therapeutic promise of inhibiting the S100A9 pathway through RAGE 
to restore radiation sensitivity, we believe that S100A9 itself could be used as a 
potential radiation response biomarker. Preliminary results of this thesis with a 
small retrospective cohort of patients showed a limited patients with low levels of 
S100A9, which might explain the frequent lack of response in patients with brain 
metastasis to this treatment modality. Even more, we were able to compare a 
sample without S100A9 and observed that, as hypothesized, response to 
radiotherapy was higher compared to another sample rich in S100A9 levels. 
Therefore, we believe that it is worthwhile to explore the potential of S100A9 as 
a biomarker of response to radiation in order to avoid the indiscriminate use of 
radiotherapy to patients that potentially will be bad responders. In fact, brain 
radiation is associated with significant comorbidities, including cognitive decline, 
loss of memory, and others, so it would be beneficial to identify those patients 
who are more likely to benefit from it.  Despite the promising results in human 
samples, it is appropriate to admit that the number of specimens is very limited 



















































1. Brain metastatic cell lines are sensitive to radiation in vitro but resistant in 
vivo; 
2. WBRT does not impact the progression of the disease; 
3. Brain metastatic cells grown in vitro as oncospheres or co-cultures with 
glial cells increase resistance to radiotherapy; 
4. Brain metastatic cells cultured ex vivo in organotypic cultures are resistant 
to radiation;  
5. We have identified a transcriptomic signature enriched in various brain 
metastasis models of radiation resistance; 
6. Targeting S100A9 decreases the resistance of brain metastasis to 
radiation both ex vivo and in vivo; 
7. S100A9-dependent radiation resistance could be blocked by BBB-
permeable RAGE inhibitor FPS-ZM1; 
8. We provide some evidence that S100A9-dependent radioresistance is 
mediated by NFκβ; 
9. We suggest the possibility that S100A9 could be used as a predictive 
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